Updating Clinical Practice Guidelines by Scattoloni, Joseph A.
Updating Clinical Practice Guidelines 
By 
Joseph A. Scattoloni 
A Master's Paper submitted to the faculty of 
The University ofNorth Carolina at Chapel Hill 
In partial fulfillment of the requirements for 
The degree of Master of Public Health in 
The Public Health Leadership Program. 
Chapel Hill 
2002 
Date 
Uodating Clinical Practice Guidelines Joseph A. Scattoloni 
ABSTRACT 
Context: Clinical Practice Guidelines (CPGs) are an expanding area ofhealthcare, 
but may be worthless and in fact hazardous if they are not current. Virtually no 
published methods or specific guides to updating them exist, and there have been 
few published tracts that document the different originating organizations' actual 
methods concerning guideline review and revision. 
Objective: To document, compare, and evaluate the CPG development and update 
methodologies of seven professional physician organizations. 
Participants: Six physician organizations were selected from the National 
Guideline Clearinghouse (NGC). An additional physician organization's methods 
are introduced from the author's experience working for said organization. 
Methods: A preliminary questionnaire was sent to selected organization 
representatives (six). Data was collected through informal, semi-structured phone 
interviews. A single organization (USPSTF) was sampled through the author's 
one-month practicum experience developing and applying review methods to 
guidelines possibly requiring update. 
Results: All organizations were very concerned with the rapidly changing 
healthcare environment and have goals of keeping their guidelines up to date. 
However, these goals generally have not been translated into explicit operational 
methods. One of seven have specified update interval; three of seven have 
systematic processes for updating; four of seven have systematic processes for 
doing an update. None have explicit methods for selecting topic experts. Time 
estimates for updates range from twelve to thirty-six months (eighteen month 
average). 
Conclusion: Guidelines have been promoted as a necessary means of improving 
healthcare for both individual patients and for the system at large, but the methods 
in place for systematically reviewing and updating previously created guidelines 
are sub-optimal. Attention to this problem is increasing as efforts to develop new 
methods have started appearing both in the literature and in several organizations 
(herein discussed). These labors in addition to increasing information technologies 
should allow ongoing review and updating of guidelines in the future. 
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INTRODUCTION 
Over the past two decades, evidence-based clinical practice guidelines 
(CPGs) have developed from an idea to a reality, and now play an ever-greater 
role in the practice of medicine. The concept of CPGs has been in place for many 
years as specialty organizations tried to codify general practice parameters to 
standardize and strengthen patient care practice. However, these guidelines were 
almost always arrived at through "expert" opinion stemming from panel 
discussions. In fact, they might be organized and written in a single session or 
day. This approach, informal consensus development1 or global subjective 
judgement2, was the precursor process for what became known as "guidelines" 
during the post-WWII years. These guidelines were not evidence-based, but rather 
reflected simple expert opinion in assessing whether a practice was appropriate. 
They also lacked methods regarding evidence assessment how consensus was 
achieved. A more formal consensus development method was advanced and 
practiced during the seventies and early eighties by several groups (the NIH, 
AMA, and Harvard Community Health Plan).1 The most formal of these methods 
(instituted by the RAND Corporation) still used panels or surveys of experts, but 
the process was more systematized and documented, often including actual 
grading scales for topics? It nevertheless failed to expressly connect 
recommendations with evidence. 
At the same time, another methodology was being developed which 
directly correlated guideline recommendations with demonstrable underlying 
evidence. The necessity of incorporating clear scientific evidence into guideline 
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development was acknowledged as early as 1980 by the American College of 
Physicians, who initiated the Clinical Efficacy Assessment Project (CEAP) to 
develop guidelines based on the assessment of clinical literature by topic experts.4 
Similar programs began to appear in specialty organizations and insurance 
groups. Even more stringent or explicit connections between evidence and 
recommendations were required in the methodology espoused by the Canadian 
Task Force on the Periodic Health Examination in 1979. Following suit, the U.S. 
Preventive Services Task Force established similar rules of evidence in 1984, 
which have become more explicit and systematic since.1 '5 In these latter systems, 
a coded schema rates the quality of evidence. 
Ultimately, clinical practice guidelines were thought to be a means of 
improving the quality of patient care. They could improve health outcomes by 
improving the consistency of care, by disseminating information to patients and 
doctors alike, and by influencing public policy.6 By the late eighties and early 
nineties, however, there was rapidly growing further interest in the development 
of these guidelines. Health care costs were becoming a greater concern for all 
parties -- payers, practitioners, and patients -- and guidelines were seen as a 
means of lowering costs and improving efficiency by reducing inappropriate care 
and controlling geographic variation in practice characteristics. With the need to 
curb costs fueling a political firestorm at the federal level in the late eighties, 
practice guideline legislation was adopted and mandated as an alternative to 
lowering costs by way of expressed expenditure targets.7 It was felt that practice 
guidelines could couple curtailing inappropriate or redundant care with improving 
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general health practices. The Agency for Health Care Policy and Research 
(AHCPR) was created under HCF A, and the government became a major player 
in the development and dissemination of CPGs. 
For all these reasons, the number of guidelines began to expand 
dramatically through the 1990s. MEDLINE searches demonstrate the rapid 
increases in published CPGs and in articles generally concerned with CPGs. 
Number of Published Guidelines per Year (1981-2001) 
Guidelines 
Year 
This from a MEDLINE search crossing the exploded MESH headings of Family Practice, Pediatrics, Psychiatry, Nursing, 
a11 surgical specialties, and all medical specialties, limiting by individual years to English, Human, and being either a 
Practice Guideline or a Guideline. 
Articles 
Published Articles with "Practice Guideline" as Subject 
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 
Year 
This from a MEDLINE search using the MESH heading Practice Guidelines and limiting by English language, Human, 
and per year. 
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With this increase in the number of guidelines, there has been a dramatic 
rise in the number of organizations who create and disseminate such practice 
parameters. Creators include any number of different allied health professional 
societies (from the Academy of Ambulatory Foot and Ankle Surgery to the 
American Academy of Pediatrics to the Society of Nuclear Medicine), 
government agencies, insurance agencies and coalitions, patient advocacy groups, 
and others. The actual use of these guidelines is hard to assess due to their limited 
access, as well as the difficulty trying to compare and contrast guidelines on 
similar topics. 
To provide a common pathway to evidence-based guidelines, AHCPR 
utilized the "new" Internet technologies to produce a central site -- the National 
Guideline Clearinghouse (NGC) -- that would gather guidelines from disparate 
sources and provide detailed and comparative methodological information on 
these guidelines. The NGC became operational in January of 1999 under the 
Agency for Healthcare Research and Quality (AHRQ) (formerly AHCPR). The 
U.S. National Guideline Clearinghouse currently lists 116 contributors and over 
900 guidelines. Some of these groups publish more than thirty guidelines. Others 
have contributed a single guideline. Browsing the NGC (at www.guideline.gov) 
assures some minimum standards for the guidelines revealed, but the actual 
number of circulating guidelines beyond the NGC is in the several thousands. 
So, it begs the question, are all these guidelines valid and of good quality? 
When the federal government entered into the guideline business, it contracted the 
Institute of Medicine to advance some general guideline concepts to inform the 
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new venture. The Institute of Medicine (IOM) standardized the definition of 
guidelines as "systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific clinical 
circumstances."8 The key word here is "systematically," for it lies at the root of 
the historic shift from an unplanned, almost anonymous process to the highly 
structured, evidence-based methods today expected. 
By their scientific nature, laboratory experiments and clinical trials strive 
to be inherently neutral processes that generate outcome or result data. It is the 
interpretation of this data that propels medicine forward and impacts patient care. 
The more quality evidence or data collected, the easier it is to make judgements. 
Evidence reports, tables, or balance sheets organize empirical data; systematic 
reviews document, collate, and summarize this data; guidelines interpret this data, 
weighing the strength of evidence for harms and benefits and costs. Each of these 
steps amplifies the possibility for error as it relies more on human judgement and 
less on quantitative assessment. 
David Eddy, one of the originators of the theory behind evidence-based 
CPGs, states that CPGs or "policies" should be accurate, accountable, predictable, 
defensible, and usable.9 They should veer as far from subjectivity as possible. 
Explicit formal analysis techniques are the best protection against subjectivity, 
inaccuracy and bias. The closer the guideline comes to meeting all these 
objectives, the higher its quality. Yet each of these objectives relies on different 
aspects of the method used to generate the guideline. This expands the resources 
requited to assure and increase each guideline's quality. 
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The generally accepted steps in guideline development are: identifying 
and refining the guideline topic; selecting and running a guideline development 
group; identifying and assessing the evidence; translating this evidence into a 
CPG; disseminating and eventually updating the CPG .10 Whenever possible, each 
of these steps should conforrri to a rigorous method that can be explicated and 
reproduced. The systematic review is the heart of the CPG's development; it 
shapes the guiding questions and then identifies and analyzes the evidence from 
which recommendations are then made. It is probably the most systematized 
aspect of guideline development for which there exist formal directions or 
illustrations.11 •12•13 Other aspects of the process are not clear and are still being 
advanced. For instance, criteria for delineating both composition and selection of 
a topic group's membership can be inadequate or haphazard. In the absence· of 
clear evidence and concerning certain aspects of quantifiable evidence (e.g. 
generalizability), expert opinion or clinical consensus will be used to make 
recommendations. However, as Shekelle et a!. state, "There is currently no 
optimal method for ... deciding how to collect and assess expert opinion."10 
Another incapacitating aspect of the process is that at present there exist only 
"passive" methods for disseminating and implementing guidelines, which result in 
minor or negligible changes in professional behavior.14 Finally, until quite 
recently there have been no systematic attempts to formulate a method for 
reviewing and updating guidelines. 15•16 
Clinical practice guidelines then can vary widely in their construction. 
Furthermore, there are the considerable costs associated with CPG development. 
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The more "systematic" the process, the greater the resources and time required. 
The costs of publishing or producing these CPGs generally do not include the 
extensive efforts of the large number of persons contributing clinical, 
methodological, epidemiological, and writing expertise.10•14 A single high quality 
systematic review contracted by AHRQ from its national Evidence Practice 
Centers (EPCs) costs approximately $250,000. 16 The demands of strict 
methodology and elevated cost limit the quality of many CPGs, but do not 
necessarily curb their creation. Many guidelines are promulgated to meet the 
narrow needs of the guideline developer and remain rooted in the tradition of 
consensus or opinion. In fact, many North American healthcare organizations 
"purchase commercially produced guidelines" that emphasize practice behavior 
that generates resource savings/profit.6 The waters have been further muddied by 
creation of "practice advisories" in which recommendations are created where 
insufficient evidence may exist. These advisories are usually arrived at via the 
older, traditional methods of clinical consensus, but have gained greater 
prominence due to their close "approximation" to evidence-based guidelines. 
CPGs should not be viewed as a panacea to the various ills of a stressed 
healthcare system. There are intrinsic limitations regarding the absence or poor 
quality of scientific evidence and the still evolving methods for gathering and 
interpreting the evidence that exists. There are also limitations stemming from 
external pressures being brought into the guideline development process. Various 
contrasting agendas may "guide" the focus or process beyond patients' needs to 
exigencies to control costs, serve societal needs, or protect special interests.7•17 
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This admixture of inadequate method and vested interest may diminish or even 
thwart the guideline's supposed primary objective (per the IOM) of improving the 
quality of individual patient care. Flawed CPGs may harm individual patient care 
in any number of ways: by overlooking good or using inaccurate evidence; by 
being inflexible; by being outdated and maintaining obsolete practices/treatments; 
by dismissing patient preferences; by disrupting doctor-patient relationships; or 
by inappropriately directing public policy and thus limiting patient education or 
resources. 6 
As demonstrated above, the number of guidelines is rapidly increasing. 
The varying forces that drive this proliferation of guidelines seem to be feeding 
from their own energy or inertia. If one or two well-constructed guidelines are 
good, then many guidelines of unproven quality are even better. For all the focus 
on evidence-based practice informing these guideline constructs, there have been 
few attempts to scientifically assess the results of these efforts. Treatment and 
diagnostic modalities are critically appraised through highly structured trials, but 
CPGs, which to a greater and greater degree generate patent care plans, are only 
beginning to be subjected to such scrutiny. So far the results are mixed. A 
systematic review by Grimshaw and Russell considered fifty-nine evaluative 
studies and concluded that "explicit guidelines do improve clinical practice," but 
that the guidelines' performances varied considerably.18 A more recent review was 
concerned only with CPGs' effect on primary care outcomes. Thirteen of ninety-
one identified studies met the inclusion criteria (reported patient outcomes); the 
9 
Updating Clinical Practice Guidelines Joseph A. Scattoloni 
results indicated that implemented CPGs "in pnmary care settings [do] not 
consistently result in improvements in clinical outcomes." 19 
It should be clear that CPGs have become a fixture in health care for the 
immediate future. While there appears to be great potential for such guidelines to 
improve patient care quality and clinical effectiveness, the development process 
and eventual implementation are still evolving and have not yet been truly 
evaluated. Many concerns need to be addressed. Some of these are being 
contemplated and investigated to a greater degree than others. My recent 
experience working with one of AHRQ's EPCs centered my attention on a 
guideline issue that has been generally overlooked in the literature until just 
recently -- the updating of guidelines, or when and how to proceed with this 
review and revision. 
In the lengthy chain of steps assuring a CPG's ultimate benefit, updating is 
a final step that cements a circular process. Review and update are ultimately 
crucial to the defined mission of improving individual patient care and 
acknowledging the evolving secondary concerns regarding consolidating or 
controlling the costs/resources associated with this care. Medicine evolves more 
and more rapidly. Over two million articles, and more than 17,000 biomedical 
books are published annually?0 The basis for guidelines, even if originally 
superbly researched and constructed, shifts and changes. Without amending and 
clearly announcing these amendments to CPGs, outmoded practices and 
technologies will be perpetuated, patient care will be compromised, and costs will 
increase due to resultant inefficiency and variations in practice. Furthermore, all 
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the resources that went into the original guideline will have been wasted. There is 
no point in creating a CPG unless one plans to maintain and update it. 
During the 1990s, resources were spent on lengthy development practices 
for CPGs. Methodologies were constructed and refined for creating the best 
possible guidelines with the available information or evidence. The necessity for 
constant or frequent review of the changing literature was acknow !edged in 
theory, and this acknowledgment led to the general specification that every 
guideline should include a scheduled review date21 ,22 But for all of the last 
decade's interest in and work on guideline development, it is the absence of any 
considered update methodology that is notable. A scheduled or binding review 
date can result in wasted resources or inappropriate care depending on the 
velocity of change in the concerned field of practice. Questions then remain 
surrounding how to decide when an update is appropriate, and then to potentially 
gauge the type of update required. Must a full repeat of the initial development 
process take place, or might the guideline only need itemized updating? 
Paul Shekelle and associates recently noted that no one had previously 
addressed how new 
information should trigger 
the update. process. They 
approached the issue by first 
suggesting an outline of 
basic principles that might 
What situations might require clinical guidelines 
to be updated? 
1) Changes in evidence on the existing benefits and harms of 
interventions. 
2) Changes in outcomes considered important 
3) Changes in available interventions 
4) Changes in evidence that current practice is optimal 
5) Changes in values placed on outcomes 
6) Changes in resources available for health care 
Shekelle et al. When should clinical guidelines be updated? BMJ. 2001; 323: 155-7. 
indicate the need for a CPG update (see box); then they proposed a model for 
II 
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guideline assessment (including decision algorithm)Y The focus of this 
assessment was on identifying new evidence and assessing whether this new 
evidence warranted updating a given guideline. Two means were advanced to 
identifY the new evidence: consulting expert opinion and performing focused 
literature searches. Experts would include previous guideline developers as well 
as other topic experts and generalists with guideline expertise. The literature 
review would be limited (in order to save time and resources) to reviews, 
editorials, commentaries, and any new guidelines on the given topic. Shekelle's 
group theorized that any new evidence significant enough to annul an existing 
national CPG must be known to established topic experts or have been published 
in significant journals with accompanying editorial comment due to its nature as a 
"sentinel marker" of new evidence. The assemblage of information may then 
inform the decision about whether or not an update is appropriate. No specified 
process was formulated to guide this decision. Shekelle's group noted that it is 
inherently subjective and relies on the clinical and methodological expertise of the 
deciding group. 
Shekelle and his associates later implemented their proposal using as test 
subjects seventeen of the original CPGs established by the AHCPR in the early 
and mid-nineties. They completed and examined a strict process that measured the 
identification of new evidence that might compel a major, minor, or no update, 
and calculated survival analysis of the rate at which guidelines became outdated.14 
Evidence was gathered per the previous discussed methods and evaluated by the 
paper's authors. When a guideline's principal diagnostic or therapeutic 
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recommendations were called into question by the new evidence, a "major" 
update or guideline withdrawal was warranted. If only secondary 
recommendations within the guideline were challenged and needed changing or 
refinement, a "minor" update was warranted. Otherwise, the guideline remained 
valid without changes. In this study, seven guidelines required major updates, six 
needed minor updates, three were still valid, and one could not be conclusively 
decided. One half of the guidelines became obsolete in 5.8 years (CI of 5.0-6.6), 
and 3.6 years (CI of 2.6-4.6) was the point at which 90% of guidelines were still 
valid. 
This was a seminal study and established a new way of considering and 
carrying out the review and revision of guidelines. However, there are still many 
troublesome aspects. Even in this regimented study, only rudimentary methods for 
expert selection were advanced. No distinction in the update process has been 
established between a "major" and "minor" update; indeed, no definition of an 
actual method to perform the updates has been advanced. This theorized process 
presupposes well-constructed guidelines where key questions informing the 
process are easily or already established. An analytic framework and resultant key 
questions are essential to gathering pertinent evidence, and this proposition and 
study fail to provide detailed steps regarding the literature search process. New 
modalities or ways of thinking about the topic may require a new "framework," 
and difficulties and time increase with the need to create analytic frameworks. 
13 
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USPSTF Update Process 
As a medical and public health student, I participated at a national 
Evidence Practice Center (EPC) that assessed whether aging guidelines from the 
U.S. Preventive Services Task Force (USPSTF) Guide to Clinical Preventive 
Services (2nd Ed.) required revision. Facing the NGC's requirement that all 
guidelines be validated at least every five years, the USPSTF sought a means of 
reconsidering older recommendations to determine their status as either still 
current or out of date and needing to be revised. Working with AHRQ, the 
contracted Research Triangle Institute!University of North Carolina (RTI!UNC) 
EPC was charged with initiating a process for just such an evaluation. A work 
group comprised of EPC staff and librarian, preventive medicine residents, and a 
medical student examined sixteen previously un-reviewed chapter topics over a 
four-month period (mid-September 2001 to mid-January 2002). Except for the 
work group leader, these participants were unfamiliar with CPG development and 
review. 
The project proceedings may be summarized as follows: 
• No clear or central organization 
• Empirically propelled experimental process 
• No clear initial oversight by the USPSTF 
• BMJ article by Shekelle et al. was a catalyst but not a blueprint for process 
• Participants worked individually on topics 
• Proposed process (while not necessarily followed for assigned 16 topics) 
was documented for the USPSTF (see box 1) 
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Observations concerning the assigned task and its process were assembled 
from my own experience writing five topic assessments, participating in weekly 
or bimonthly work group meetings, and informally surveying other work group 
participants. 
Proposed Updating Process for USPSTF (12/15/01) 
I) Read old chapter, draw Analytic Framework, define "critical" key questions (KQs) 
2) Send old chapter to 2-3 experts in the field, asking standard questionS about the existence of new 
evidence, ongoing studies, and their opinion of whether revision is needed 
3) Do Cochrane search for systematic reviews and new RCTs for critical KQs 
4) Do MEDLINE search for systematic reviews, editorials, commentaries, and new evidence (since 
1994) on critical KQs, using restrictive search terms and incJusion criteria designed to :find_ high 
quality evidence 
5) Search the NGC and key organizations for new guidelines at variance with the USPSTF 
6) Examine editorials, connnentaries, and reviews for new high quality evidence not found elsewhere 
7) Examine references from experts and other guidelines 
8) Write brief abstract of high quality new evidence for each critical KQ 
9) Briefly summarize new evidence for each critical KQ, including information from experts and other 
guidelines 
1 0) Task Force subconnnittee examines summary of evidence and reviews key studies if needed 
11) Present sununary of new evidence (1-2 pages) to entire Task Force at a meeting for discussion; topic 
is assigned a priority code for revision update 
Box I 
SIGNIFICANT ASPECTS of PROCESS 
Defining Critical Questions 
Guidelines are created to assist in answering questions. To reassess them 
demands a clear understanding of each guideline's context and the questions it is 
attempting to acknowledge. This skeletal or analytic framework (AF) becomes the 
basis for strategies developed to create and, in our case, re-assess guidelines 
through the critical questions they attempt to answer. Several difficulties were 
noted: 
• Overarching or key questions were difficult to agree upon. 
• Uncertainty hindered the ability to decide where to draw the line when 
incorporating topic material for assessment: 
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• Certain topics were extremely broad. 
• Some topics had sustained rapid changes underlying 
concepts/application. 
• The introduction to and application of analytic framework (AF) came too 
late in the process to make a difference. 
• Working alone, each participant felt uneasy about the reliability of the 
process. 
Literature Searches 
Our supposed task was to gather in the most efficient or economical 
manner the best quality evidence to inform a recommendation. It begs the 
question: how is "high quality" evidence defined and then identified? The 
definitions and hence the type of evidence may vary per topic. "Counseling 
outcomes" may be much more difficult to quantify than the diagnostic effects of a 
blood test in "screening outcomes." The Shekelle et a!. criteria enlist editorials 
and commentaries in "major journals" to route this search directly to "quality" 
evidence. Our work group defined "quality" by randomized controlled trials 
(RCTs) or other closely controlled trials and our searches encompassed "all" the 
literature. Two real problems stood out: 
• Whether to limit or expand searches. Tied to the aforementioned 
difficulties with developing topic frameworks and key questions, searches 
were initially quite limited. However, with evolving expansion of many 
topics' crucial points, additional searches crossing separate headings for 
treatments, or harms, or other "buried" information became necessary. 
• When to halt searches. This raises the question of whether the undertaken 
process is simply to document a need for updating, or to actually perform 
a significant portion of the update itself. If the literature provides one or . 
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two clear examples of high quality evidence changing the supposed 
guideline, isn't the process completed? 
Experts 
Experts may redefine a topic's parameters, identify new evidence, and 
assess the evidence in 
Exceroted from letter sent to Experts 
the context of such We will be grateful if you could advise us concerning the following 
questions. Do you have knowledge of: 
parameters. Two to four 
experts were selected for 
each topic and were 
mailed (by post and/or 
e-mail) copies of the 
prev10us Task Force 
·new evidence (i.e., since 1994) or developments in the field that 
relate to the prior USPSTF evidence review and recommendation; 
· new evidence that is expected to be published in the near future; 
- any changes in available interventions; 
· any changes in the evidence on the benefits and harms of treatment. 
In addition, any guidance or references to materials published in the 
past seven years that you believe will illuminate this particular 
clinical topic will be appreciated. 
Finally, in your opinion, how great is the need to update this chapter 
in the· next 1 to 2 years - great, some but not urgent, or not really 
needed? 
Box2 
guideline and specific questions for the applicable topic/chapter (see box 2). 
The response rate was poor (see box 3) and variation of expert response 
was extreme from three page references and full text unpublished articles to single 
Consulted Experts' Response 
16/48 (33%) ~Total Response Rate 
4/18 (22%) =Response rate for experts outside the U.S. 
4/16 (25%) ~Response rate to Email 
1 mo =Average time to respond for those who responded 
Box3 
sentence replies. No means was 
implemented to check if method of 
contact or format of questions would 
have changed the outcome. It should 
be noted that no compensation was 
offered to these experts and this may have increased the response rate. 
There was no established method for selecting or validating these experts. 
Networking or word of mouth advised the selection of some, while the majority of 
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experts resulted from scanrung article authors from literature searches. Work 
force members used their own methods to select experts. This increased the 
inconsistencies and probable bias, and may have contributed to the poor response 
rate. 
Oversight by issuing or contracting agency 
The work group was ultimately contracted by the USPSTF to serve their 
requirements. This actually created operational difficulties within our work group: 
• There were no specific instructions regarding the scope of each chapter or 
guideline review. 
• When there was interaction, the rules kept changing, causing continual 
process modifications. 
In fact several designs would have greatly facilitated the process: 
• The contracting agency (USPSTF) should provide direction and 
expectations at the very beginning of the process. 
• This agency should at outset provide immediate input into the 
development of AF, key questions, and search parameters. 
• Guidelines ought to document original or subsequent AFs and key 
question evo !uti on. 
Results 
The sixteen topic briefs or summaries were presented to the USPSTF in 
late January 2002, and their disposition may be viewed in box 4. Three of the 
sixteen, while close to resolution, required some further work. While under 
discussion, there was no definition advanced for the specific types of changes or 
required further work entailed in tweaks, minor, or major updates. Rough 
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estimates among work force members 
regarding time demands (literature 
searches, article pulling and review, 
meetings/conferences, and writing) 
were: 
• 
• 
Approximately fifteen hours 
for simple topics (e.g. 
screening for testicular or 
pancreatic cancer). 
More than forty to fifty hours 
for complicated or evidence 
rich topics (e.g. tuberculosis, 
AAA, or screerung ultra-
sonograpy in pregnancy). 
Comments 
Joseph A. Scattoloni 
Process Results 
Five "Minor Tweaks"- essentially guideline still 
valid 
1) Screening for Phenylketonuria 
2) Screening for Congenital Hypothyroidism 
3) Screening for pancreatic Cancer 
4) Screening for Testicular Cancer 
5) Screening for Oral Cancer 
Five "Minor" Updates 
1) Screening for Gonorrhea 
2) Screening for HIV infection 
3) Counseling to prevent HIV infection 
4) Screening for Preeclampsia 
5) Screening for Tuberculosis 
Three "Major" Updates 
1) Screening for Peripheral Artery Disease 
2) Aspirin prophylaxis in pregnancy 
3) Screening for Abdominal Aortic Aneurysm 
Three required re-evaluation or additional search of 
evidence to decide 
1) Screening for Hepatitis B infection 
2) Counseling to prevent low back pain 
3) Screening Ultrasonography in Pregnancy 
Box4 
It is true that we did not implement a systematic trial of a specified process 
like the process described in Shekelle et al's JAMA article; in fact, it was an 
evolving process. Nevertheless, it raises some important issues. First, are key 
questions and analytic framework of existing guidelines easily identified? They 
are requisite for the construction of. an effective and evolving search for new 
information. Indeed, they go to the heart of understanding the basis of the original 
guideline and how it must evolve with the changing medical literature. To 
streamline the process and avoid a vacillating definition of review goals, early 
definitions must be established. Moreover, there should be agreement among 
independent reviewers concerning this framework and the resulting key questions. 
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Studies should be undertaken to evaluate this process for inter-observer 
agreement. 
The foundation for any necessary changes to a guideline derives from a 
reliable assertion of new evidence. Therefore, studies should also be implemented 
to discern the inter-observer agreement (reliability) between reviewers who use 
these "established key questions" to identify credible or high quality new 
evidence. 
For all the gathered evidence and all procedures used to minimize the 
introduction of bias to the process, decisions about how to develop criteria or 
identify and assess evidence are inherently subjective. "Experts" on the specific 
topics and on guideline methods will be required, but a specified selection process 
should be formulated. Experts should not be picked through a haphazard manner, 
nor should they be selected through "word of mouth" in an insular network. Once 
again, if good criteria are created for approaching this selection, then there should 
be inter-observer agreement among reviewers. 
Incorporating both literature review and expert opinion expands the ability 
to capture and evaluate relevant new evidence, but it should be considered 
whether there is a significant difference between the results of expert query versus 
focused literature search. What is the best manner of contacting and questioning 
selected experts? Was our poor response rate due to the method of contact? And 
how many expert opinions are enough to sufficiently inform the process? 
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The UPDATE PROCESS at other ORGANIZATIONS 
Given my experience in.the EPC work group, I wondered how or even if other 
organizations that generate CPGs were addressing the "update question." I 
resolved to begin a small-scale evaluation ofthis question. 
METHODS 
To more fully understand the processes surrounding the development and 
updating of clinical practice guidelines, I interviewed representatives from a 
sample of six organizations that write guidelines. These professional medical 
societies or organizations had at least ten guidelines published on the National 
Guideline Clearinghouse. I · assumed that physician organizations would 
incorporate the most stringent, well-developed, and reproducible methodologies 
or processes regarding guideline construction and maintenance. Selections after 
these baseline criteria were not methodical but ordered according to leading or 
earliest position in the NGC and a probable bias regarding organization reputation 
or influence. The six organizations were: 
• The American Academy of Pediatrics (AAP) 
• The American Association of Clinical Endocrinologists (AACE) 
• The American College of Cardiology (ACC) 
• The American College of Physicians/American Society of Internal 
Medicine (ACP-ASIM) 
• The American Psychiatric Association (AP A) . 
• The American Society of Anesthesiologists (ASA). 
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The contact information for each of the organization's headquarters was 
located using Internet web searches. I telephoned the central operator at each 
organization, introduced myself, and asked for the e-mail and direct extension to 
the most appropriate person to speak with regarding the organization's 
maintenance of clinical practice 
guidelines. Before every 
interview, the assigned 
representative received by e-
mail a standard temp late of 
quenes (shown here) to better 
inform them of the general 
parameters of my questioning. 
The subsequent conversations 
were informal and semi-
structured around my list of 
questions. In several instances, 
the calls were conducted in two 
sessions due to respondent time 
constraints. What follows are 
general notes and impressions 
from these conversations. 
RESULTS 
GUIDELINE UPDATE QUESTJONAJRE 
for Creating Organizations 
1. When were guidelines last updated? 
(mo/yr) (never updated) 
2. When will the next update occur? 
(mo/yr) (not yet determined) 
3. Is there a schedule dictating when specific guidelines are to be 
updated? 
4. If there is not a schedule, is there a specified system your 
agency uses to review guideline topics in order to check 
whether they need an update? 
• Who or what group conducts this review to decide 
whether an update is warranted? 
(intra-agency) (outside agency) 
• Does this same person or group then undertake the 
update process itself? 
5. If an update is required, does your agency utilize a standard 
methodology to direct the update process? 
• Is the process written? 
• Can you send it to me? 
6. Please describe briefly this methodology if pOssible - the 
following questions may or may not inform your description. 
• Are topics updated through a literature search? 
• Is a complete systematic review undertaken? 
• What are the parameters or criteria of such a search? 
(single key quest) (multiple key quests) 
(only RCTS, Reviews, Edits/Comments) 
(some combo of article or study types) 
• Are topic updates informed through the solicitation 
of expert opinion? 
How are experts selected? 
• How many are selected? 
• How many generally respond? 
After researching the topic, is there a system 
describing or categorizing the amount of revision 
each guideline requires? Who does this revision? 
Who must approve it? 
(complete update via systematic review) 
{complete update per collected evidence or 
expert opinion) 
(moderate update) (minor update) 
(no update required) (other categories) 
7. How long does it take to update a guideline? 
8. Can you estimate the costs for updating a topic? 
($) (person hours) 
9. Who makes the final decision whether a guideline update is 
adopted and what it w111 recommend? 
(committee) (individual) (outside agency) 
(See Table 1 for overview of organizations) 
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AMERICAN ACADEMY ofPEDIATRICS 
At the AAP, I spoke with Carla Herrerias, MPH, Senior Health Policy 
Analyst, who told me that the first guidelines from the AAP began appearing in 
1994. At that time, it was established that guidelines would be assessed every 
three years and be either "revised, retired, or re-affirmed." Such assessment would 
incorporate the same methodology as the initial development of the said guideline 
with the only concession being an amendment of the employed literature search 
strategy by limiting the dates of the search to a minimal overlap with the previous 
search parameters. Thus, each guideline update is a complete "re-development" of 
the original evidence-based guideline. Every guideline must begin such re-
assessment every three years. All the AAP's guidelines from the years 1994-1999 
have been through or are being put through such a process. 
Ms. Herrerias stated that evidence-based Practice Guidelines take 
approximately twenty-four to thirty-six months to develop and publish. This time 
estimate holds for the "updates" or three-year re-assessments. She emphasized 
that each guideline was different depending on its complexity and the new 
evidence amassed, as well as the dynamics of each guideline workgroup. 
However, literature review and analysis generally takes twelve months, and an 
additional eighteen to twenty-four months are required for discussion, writing, 
and adoption of the new guideline (or its reaffirmation or retirement). Because of 
the extensive and time-consuming method, the process of reassessment usually 
begins soon after the guideline is published (within twelve to eighteen months). 
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Guideline topics originate m the National Quality Improvement 
Committee, and workgroup members (who are considered experts for said topic) 
are selected via nominations from the AAP's national committees and/or sections. 
These nominations are reviewed by the Quality Improvement Committee and 
finally approved by the AAP board of directors. This sub-committee or 
workgroup usually numbers ten to fifteen persons including an epidemiologist 
and, unless conflicts arise, these members comprise the sub-committee assigned 
to continual updating. Members are asked to continue "observing" the literature in 
preparation for updating the guideline. They are replaced individually as needed 
through the nomination process mentioned above. 
A comprehensive methodology example and flow chart of the actual 
process from beginning to end was sent to me by Ms. Herrerias and is shown in 
appendix 1. The literature review is described as "in-depth" and is based on the 
criteria specified in the guideline. From Ms. Herrerias' description, it is a full 
systematic review of the literature although we did not discuss specific types of 
studies considered applicable to these reviews. The experts queried are those on 
the sub-committee itself. As alluded to above, a three tier system is used to 
categorize an update -- revision (essentially a complete rewrite), recaffirmation 
(keeping the old guideline intact), and retirement (withdrawing the entire 
guideline from further sanctioned use). All these changes or recommendations 
originate in the sub-committee and go to national specialty committees and 
societies and other outside agencies for review. Final changes are made by the 
subcommittee and are reviewed first by the Steering Committee on Quality 
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Improvement and Management, then the Board of Directors, and finally the AAP 
Executive Committee. 
Ms. Herrerias mentioned that costs for updating guidelines are extremely 
hard to estimate and that there have not been any attempts to quantify these costs 
up to now. The AAP relies on the volunteer activities of many clinicians inside 
and outside the AAP for panel participation and assistance with each literature 
review. There are paid epidemiologists, librarians, and support staff involved. 
When further queried, she estimated a minimum of $30,000 for each update, but 
the number is probably much higher. The AAP has been partnering with or 
contracting the services of AHRQ and its EPCs to a greater and greater degree for 
guideline development and review purposes, and she noted that their estimates for 
a complete systematic review in the process of guideline development was 
somewhere around $250,000 per guideline. 
Asked if she thought the present system was effective, Ms. Herrerias said 
that it was quite thorough and, in fact, perhaps too thorough. A great deal of time 
and resources (monetary and clinician time) are expended on the update process, 
much of which may be redundant. She is not sure that each guideline needs to be 
completely revamped, and there has been increasing concern within the AAP 
about the resources being utilized. Discussion has ensued concerning other more 
streamlined ways to conduct the update process -- using a more focused literature 
search, polling experts about new evidence rather than performing a literature 
search, reviewing and/or changing sections of guidelines instead of the whole. 
However, none of these changes are presently on the table to be implemented. ln 
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her capacity, Ms. Herrerias interacts with other organizations that develop and 
update guidelines, and she stated that the difficulties and questions concerning 
updating methods are presently mounting and gaining greater attention. 
AMERJCAN ASSOCIATION of CLINICAL ENDOCRINOLOGISTS 
Sissy Crabtree is the AACE's Director of Communications. She stated that 
the AACE has published thirteen guidelines over the past eight years. There is no 
specific schedule or process for reviewing these guidelines in order to assess the 
need for update. It is an informal process with a suggested "scheduled review" or 
"expiration date" of five years from publishing date. In fact, there is not a 
specified methodology for the creation of these guidelines; there are simply 
approximate standards for their construction. 
Guidelines originate when the AACE Board of Directors selects a 
chairperson, who is a topic expert (and sometimes a Board member), to oversee a 
work group of experts chosen from candidates nominated by this chairperson and 
the Board. No detailed selection method exists for these individuals. This work 
group usually comprises some five to ten members. The specific methodology the 
work group follows is explicated by the chairman and does not necessarily hold 
true for other work groups. Literature search parameters may vary, as may 
assessment techniques per the personal views of this chairperson. 
Ms. Crabtree did send me the "AACE Standards on Medical Guidelines 
for Clinical Practice," which was developed from information from the AMA 
(appendix 2). This description seems to serve a purely suggestive function and 
does not elaborate or explicate any portion of the process. For instance, #1 0 on 
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this list deals specifically with update concerns by proposing that an expiration 
date or scheduled review date (within five years) be written into the guideline. 
Furthermore, it states, "[A] system is established to monitor the emergence of 
[new] information, which may necessitate revision." It does not propose such a 
system, and in fact, as described above, the AACE does not follow a prescribed 
system either, granting each chairperson their own autonomy in judging new 
evidence toward the decision to update older guidelines. Ms. Crabtree describes 
the processes actually in place as quite "informal." The "standards" document also 
states that guidelines should outline methods for evaluating their own impact and 
using this evaluation in the revision discussion and implementation. There is 
nothing in place at the AACE to even begin such an evaluation. 
When guidelines (or updates) have been completed in the work group, 
they go to the Publications Committee, which checks for technical accuracy and 
content, and the chairperson of this committee has a dialogue with the work group 
chairperson to make further revisions. From there it goes to the Medical Editor of 
the journal who reviews it before publishing. All members of the AACE Board 
(33-35 members) have the "opportunity" to review it and comment, but this is not 
a presumed or explicit part of the process. 
Guideline development at the AACE takes around twelve months, and Ms. 
Crabtree said that updates take similar amounts of time but may be quicker 
depending on the chairperson. As revealed at other agencies, costs are extremely 
difficult to estimate, but she said that publishing costs (including medical writer) 
of each guideline run around $25,000. Of course, there are costs associated with 
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support staff and the many volunteer hours of work group members' time. Ms. 
Crabtree suspected that each guideline's total cost might hover around $100,000. 
AMERICAN COLLEGE of CARDIOLOGY I AMERICAN HEART 
ASSOCIATION 
Charlene May, Director of Document Development and Practice 
Guidelines, explained that she is involved with the document management 
"process" and that I should also speak with Paula Thompson, MPH (chief 
methodologist/analyst). Ms. Thompson is involved with "methods" and has been 
instrumental in the construction of the ACC's web site documenting their 
guideline development methods. I spent time conversing with both Ms. May and 
Ms. Thompson. 
The ACC published its first guideline in 1981. At present there are 
seventeen that the ACC/AHA have produced, but the process of development for 
these CPGs has evolved over this time period. Ms. Thompson reported that it has 
only been in the last several years that a research analyst or methodologist has 
become a mandatory component in each of the ACC guideline-writing 
committees. Prior to this change, these committees policed themselves regarding 
their "undocumented" methods. This new emphasis has allowed for a clearer 
documentation of the methodologies employed by the ACC/AHA in the guideline 
development/update process. This documentation is available to peruse on the 
organization's website, www.acc.org (downloaded to appendix 3). In fact, it is 
quite thorough in its description of the methods employed for guideline 
development and updates. 
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Originally, guidelines were to be reviewed for update every five years; 
then the interval changed to two years, but this has been amended to one year 
after publication and every subsequent year thereafter. The system to determine 
whether an update is required begins with two persons, the writing committee's 
chair and its research analyst. These two identify ten to twelve important journals 
relevant to the topic (advised by the initial guideline's literature analysis) and then 
monitor them over the course or at the end of the year following initial 
publication. Articles that might change a guideline recommendation or signal a 
major shift in thought process would indicate the need for an update. The entire 
writing committee is also surveyed every year for their input regarding any 
momentous changes in the evidence that would signal the need to update. The 
writing committee's formal recommendation goes to the parent committee (Task 
Force on Practice Guidelines), which decides whether to update or not. 
When required, the actual update process proceeds down one of two paths, 
either "update" or "revision." Either path incorporates the same strict 
methodology of evidence procurement and analysis as the initial guideline 
development. "Updates" stem from a necessity to change one or more of the 
recommendations of a specific guideline. These changes are incorporated into the 
original document with clear reference to the new evidence. They are published in 
three forms: the original or preceding guideline with old sections struck out and 
the new in bold print (this demonstrates the changes); the new altered version; and 
a summary of how and why the old version has been changed. 
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"Revisions" are complete rewrites of the guideline and are used when the 
document no longer reflects the standard of care it supposedly covers. Ms. 
Thompson citedthe recent "Heart failure" revision (2001), which required are-
conceptualization of the guideline's purpose due to fundamental changes in the 
understanding of the condition. This guideline was started from scratch; new 
clinical objectives were debated and developed, and these raised the questions that 
guided a full systematic review. But such total revisions are fewer now as 
increased staff and more constant review of the literature allow for flexible and 
continued quality "updating" of guidelines. Still, Ms Davis explained, only two 
"updates" are allowed each guideline before a total revision is mandated. 
The Task Force on Practice Parameters creates writing committees 
composed of eight to twelve members by first determining guideline topics and 
then (with the assistance of the ACC and AHA presidents) nominating and 
selecting a chairman who will assist the Task Force in the selection of the 
remaining committee members from the Colleges. Up to three "outside" specialty 
organizations (not necessarily physicians) are invited to send a working 
representative to the writing committee. These are the only members who submit 
CVs and interview. The committee is responsible for the guideline's Content 
following the set methods. As with other organizations, there is no specified or 
objective method for the selection of these members. They are the "acknowledged 
tops" in their academic or clinical endeavors. The writing committee stays intact 
in order to facilitate continued review of the literature and the possibility ·of 
updates, but membership changes each year after the first year's anniversary with 
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revolving reappointment of one-third and two-thirds of committee members in 
opposite years. 
Each guideline or update making its way out of the Task Force undergoes 
a lengthy peer-review process. First there is "content" review by multiple (as 
many as ten) "experts" selected by each of the writing committee members. Their 
input is debated and possibly incorporated. Then there is the "official" review. 
The guideline draft goes to three experts from the AHA, three from the ACC, and 
one each from any "outside" agency included in the writing committee. The 
chairman is responsible for responding to all "official" reviewers and making any 
requisite changes with the writing committee. The AHA and ACC board of 
trustees (thirty members) debate this draft and hash out any further differences 
with the chairman and College presidents before making a resolution to accept a 
finished document. It should be noted that although this procedure is elaborate 
and quite thorough, there is nonetheless a lack of explicit criteria for the selection 
of these reviewers/experts. 
All documents are "team-written" with each phase and every subsection 
divided among members so that consensus development is ongoing. Ms. 
Thompson admitted, however, that this also slows and potentially politicizes the 
process. An initial guideline development or full revision takes eighteen to 
twenty-four months, while updates take approximately one year or less. Only 
certain sections of updates demand a review and rewrite. Ms. Thompson also 
stated that the disparate factors involved in facilitating quick guideline 
reviews/updates center primarily on the interpersonal skills of the committee 
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chairman, but also on group members. One member can completely logjam the 
work product. Finally, staff support is crucial, as a methodologist, for instance, 
may provide a steadiness or continuity to the group. 
Ms. May stated that update costs would be impossible to estimate at this 
time, but that a conservative estimate of a full guideline development or revision 
would be around $100,000. This would include the time of one science staffer, 
one project manager, and some support staff, but only minimum inclusion of 
overhead. She reminded me that a great portion of the work is done by College 
members whose time is strictly voluntary and un-reimbursed except for direct 
expenses like travel and lodging to conference/discussion meetings. Some monies 
have been recently saved because the College does not publish hard copies of the 
full guidelines any more. It relies on electronic media for this. 
AMERlCAN COLLEGE of PHYSICIANS I AMERlCAN SOCIETY of 
INTERNAL MEDICINE 
The operator at the ASIM directed me to the scientific policy department 
where I received contact information for Vincenza Snow, M.D:, Senior Medical 
Associate, Department of Scientific Policy. The ACP-ASIM has been in the 
guideline creation business since 1981 and currently supports fifteen guidelines. 
But its archives include forty-three previously published guidelines that have 
expired. Dr. Snow explained that a strict "sundowning" policy dictates that every 
practice guideline will be withdrawn after five years of its most recent publication 
unless a formal review and update results in a new publication in the Annals of 
Internal Medicine. So, specific guidelines do not exist for more than five years 
and an update is not a guaranteed event. 
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Dr. Snow described a loose but straightforward and constant process to 
review current guidelines for necessary updates. First, an abbreviated or focused 
literature search of the major journals (Annals, BMJ, JAMA, NEJM, and Lancet) is 
ongoing for anything that points to new evidence regarding the specific topic. 
Any such information is presented at the quarterly meetings of the Clinical 
Efficacy Assessment Subcommittee (CEAS) and after discussion this information 
may trigger a formal directive to update. These literature searches may also turn 
up newly published and well-regarded guidelines that may circumvent the need 
for any update, thus predestining the ASJM guideline to withdrawal upon 
expiration. Dr. Snow cited recent screening guidelines disseminated by the U.S. 
Preventive Services Task Force as examples of this proceeding. Finally, all 
guidelines are formally reviewed in committee two years before expiration 
through the amassed results of these focused literature searches and committee 
members' expertise and knowledge of the topic. 
One must understand that the ASIM develops and updates guidelines in a 
manner slightly different from other organizations. Their guidelines originate 
either in an opportunistic or de novo fashion. "Opportunistic" supposes that a 
clear, wellcsupported evidence or systematic review is available or being 
developed relevant to a desired topic of the ASIM. Obvious examples of such 
reviews are Evidence-based Practice Center (EPC) reports contracted by the 
Agency for Healthcare Research and Quality (AHRQ). These evidence reports 
form the basis of "background papers" created by the original EPC 
authors/researchers that may then be assimilated into a policy piece written and 
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adopted by the ASIM. Dr. Snow used the example of "pharmacotherapy for 
depression." The original review of the evidence concerned patient groups beyond 
the Society's purvey (children, pregnant women, etc.). So, the EPC authors were 
asked to write a summary of their findings regarding adults. 
The de novo process starts within the ASIM and utilizes members' 
expertise and efforts. Dr. Snow and CEAS members research (via own 
knowledge, literature, contacts) possible topic or content experts from within the 
membership who might carry out a systematic review of the evidence. The CEAS 
examines nominated physicians' CVs and publications and selects the task force. 
This usually comprises two or three people with an additional methodologist. This 
group is responsible for the "background paper" that will be integrated into the 
policy statement (or final guideline). 
Whether developed via intra- or extra- organization, Dr. Snow considers 
the background papers through each draft. Likewise, Dr. Snow and the Scientific 
Policy Staff are responsible for the construction of all policy statements and the 
integration of these background papers. This arrangement around a single 
person/entity streamlines the process and avoids unnecessary procedural hitches 
that might develop with multiple creators. Dr. Snow acts as an advocate or 
gatekeeper for each of the guidelines, and through her position the ASIM 
guidelines acquire continuity and consistency. 
Regarding updates, there is no system in place to categorize the amount of 
necessary revision; a total rewrite is initiated. The background or evidence authors 
are released after the publication of the guideline and background paper or 
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corresponding updates. If a further revision is required, these original authors are 
invited, if unwilling or unable, to recommend another group to perform the 
evidence assessment. Literature reviews for updates begin where the original 
search left off 
There is currently no written or standard ASJM methodology to direct 
reviewers through guideline development or update. The ASJM's history with 
certain groups like the EPCs informs its understanding and sanctioning of their 
employed methods, which include standardized scoring of the literature, evidence 
tables, and consensus statements where there are gaps in the evidence. 
Nevertheless, the CEAS does participate in and to a certain extent coaches the 
progress and process of the evidence analysis in the "background papers" through 
early and continued communication with the background or evidence authors. The 
CEAS endorses the topic's analytic framework, key questions, and evidence 
linkages, and they view and comment on each draft of these papers. Nevertheless, 
Dr. Snow stated that the Scientific Policy Staff is in the process of developing a 
"guideline of authorship" which will explicitly chart a methodology for guideline 
development/update. For now the ASJM's loose descriptions of its efforts and 
general methods (appendix 4) can be found at its website (www.acponline.org/sci-
policy/ guidelines). 
It takes approximately eighteen months to develop these guidelines and 
shepherd them through the required review process. The CEAS approves the final 
background paper for method and content. It works with Dr. Snow to finish a 
policy or guideline statement that must then be approved successively by the 
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Education Committee and the Board of Regents. A further evaluation of the 
employed method and content takes place when the guideline is submitted to the 
Annals of Internal Medicine, which has autonomy in its acceptance or rejection of 
the College's statement. 
Dr. Snow was unable to provide any estimates of guideline costs. She and 
her staff are working on nine to eleven guidelines in various stages at any one 
time, and a great portion of the work is completed through volunteerism by 
College members or by outside agencies (like the EPCs) working from their own 
budgets. She was also unable to provide any substantive information regarding the 
actual use or effects of the guidelines she had helped to produce. While the 
ASIM's Physicians' Quality Network (Qnet) may examine the issue of guideline 
dissemination, implementation, and outcomes assessment in the future, there are 
currently no specific plans for such studies due to lack of funding. This greatly 
concerns her because the time and effort going into the construction of such 
guidelines may be completely wasted as these practice guidelines "are left on the 
bookshelves," fail to be implemented, or worse, actually diminish patient care. 
AMERICAN PSYCHIATRIC ASSOCIATION 
The operator at the AP A connected me with Rebecca Thaler, MPH, Senior 
Project Manager for Practice Guidelines. I sent her my e-mail questionnaire, and 
she sent me the AP A's methodology guides before we finally spoke at length. 
The AP A' s first practice guideline was completed in 1994 and eleven 
more have been published since then with four more new guidelines to be 
published in the next two years. Two previous guidelines have already undergone 
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updating/revision and five more are in the midst of updating with planned 
publishing dates ranging from 2002 to 2004. When the AP A originally published 
these guidelines, they had planned on mandating an update every three to five 
years incorporating major or minor changes depending on the shifts in or 
evolution of the pertinent literature/thought process. Every ten years, a complete 
guideline rewrite would be undertaken. Ms. Thaler explained that this projected 
update schedule has been remodeled. Due to the exorbitant resources required for 
a thorough and complete evaluation of the guidelines, the concept of making 
major/minor changes every three years has been abandoned for simply 
implementing a full revision or rewrite process when the need presses. 
Who then decides when this need becomes pressing enough? Or likewise, 
IS there a system in place to check the necessity of an update? Per my 
conversation, the decision or impetus to update is derived from the expertise of 
the Steering Committee, writing workgroup, and other clinician/researchers 
regarding new diagnostic or treatment modalities. There is not a system per se 
besides the concerns of conferring experts or associates who many times have not 
been formally consulted. Nevertheless, the five-year yardstick remains in place to 
measure approximately when serious consideration or . discussion should 
commence concerning an update (if it has not previously been initiated). 
While the update process is not "set in stone," it closely adheres to the 
specific methodology outlined for initial guideline development at the AP A. This 
strategy (derived from the AMA and IOM) is outlined in the APA Practice 
Guideline Development Process (appendix 5) and is fairly explicit. Ms. Thaler 
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said that the reviSlon or update process differs from the initial guideline 
development only in that literature searches may be "more abbreviated" by way of 
shortened search-date intervals, or specific treatment or other key questions. 
There are also usually fewer drafts simply because the work group has the 
previous guideline for reference. 
From the documents provided, it is clear that the AP A does try to follow a 
rigorous evidence-based procedure, but that "where gaps exist in the research 
data, evidence is derived from clinical consensus." So, expert opinion is 
"quantified" as part of the process through an extensive series of draft reviews by 
the work group, the Steering Committee, fifty reviewers "with expertise in the 
subject area," a variety of other AP A committees/councils, and one hundred 
"representatives of related organizations." This scrutiny is impressive and 
probably more complete than most reviews, and yet there is no articulated 
procedure or criteria for selecting these experts. 
Ms. Thaler reported that guidelines generally take more than twenty-four 
months to develop from scratch and approximately eighteen months to update or 
revise. She was unable to provide accurate costs associated with the process. 
There is no specific budget per guideline developed or updated, but she concedes 
$50,000-75,000 per update would be a very rough estimate. Of course, this does 
not include the number of voluntary hours by work group and other AP A 
members, which is considerable and varies from topic to topic. 
Regarding the lengthy process around guideline updates, Ms. Thaler 
acknowledged the difficulties implicit in staying abreast of new information in the 
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guidelines while adhering to the high standard required by updates incorporating 
the "full review" or rewrite process. This is especially difficult with guidelines 
like the AP A's, which are quite exhaustive and run fifty to seventy pages in 
length. The emerging question within the AP A has been how to stay current 
between these exhaustive reviews. A more streamlined "advisory" is being 
developed which would act to supplement guidelines with specific new treatment 
or diagnostic information derived from "limited" literature searches and expert 
opinion. These "Watches" would not be guidelines or carry the weight. or 
consensus of sanctioned guidelines, but would only provide a central information 
hub to clinicians, and might finally assist or be part of the decision-making 
process informing when a full update is warranted. Such "Watches" have not beeu 
put in place but are currently being developed. 
AMERICAN SOCIETY of ANESTHESIOLOGISTS 
Richard Connis, Ph.D., Chief Methodologist, Committee on Practice 
Parameters, discussed the ASA's procedures regarding guidelines and updates. 
The ASA's first guidelines were published in 1993. Since then twelve 
more have been published. During the past nine years only one (sedation and 
analgesia) has been updated (adopted in October 2001, to be published 
upcoming), but three more are in the process of being updated with possible 
publication over the next two years. There is no specific schedule mandated for 
updating these guidelines, and no explicated process exists for reviewing present 
guidelines to assess their current applicability. 
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The ASA Committee on Practice Parameters was established in the early 
1990s to oversee the development of all ASA guidelines. Along with other agenda 
items at its annual meetings, this committee decides which topics merit 
consideration as guideline topics and then appoints a chairperson (most often not 
a member of the committee) to oversee a task force numbering eight to twelve 
members in the development of said guideline. The committee with this chairman 
then nominates recognized topic experts from the United States and Canada to 
serve on this task force. There are no set criteria or systems for the selection of 
these experts. Even after guideline completion, this task force is never disbanded; 
it remains in place as a resource on this topic to help decide when and how to 
revise the guideline. One member of the task force is designated as an oversight 
person to communicate task force views or progress to the Parameters Committee. 
Topic updating is guided by the expressed need of members of this task 
force or members of the Practice Parameters Committee. If committee members, 
through their own concern, think an update is required, it is discussed and put 
forward to the task force. Likewise, if task force members (the experts on the 
topic) feel new evidence demands assessment, they communicate with the larger 
Committee to start the ball rolling back to the task force. The task force makes a 
recommendation to the committee after meeting with all its members to discuss 
possible updates. So, the impetus driving an update is a two-way street between 
these groups, but without explicit process. Updates may occur as early as one to 
two years after the most recent publication. The Practice Parameters Committee 
must formally consider every guideline within five years of its last formal 
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assessment. The assigned methodologist for each task force will raise the five-
year formal inquiry in the event that no one has expressed an interest in guideline 
revision prior to this time. 
An update at the ASA entails a complete guideline revision whereby the 
assigned task force starts from scratch as if they were developing the initial 
guideline. The only difference from previous development resides in the limiting 
dates of the literature search, which start one year before the most recent date of 
publishing. The actual process or methodology of development has been 
previously published (appendix 6).23 The ASA is different from most other 
organizations in that it employs a three-tier process of guideline development --
directional assessment ofliterature syntheses, meta-analysis, and expert consensus 
as evidence. The initial literature search is quite broad, excluding only editorials, 
commentaries, correspondence, reVIews, meta-analysis, and unpublished 
papers/presentations, and including even case reports and descriptive studies. 
Well-designed studies including statistical information are pooled into a formal 
meta-analysis. The writing process incorporates interaction between the task force 
writers (chairman and methodologist), task force members, and other ASA 
members (via internet). A long chain of open forums with input leads to a final · 
vote by the ASA House of Delegates. 
If the guideline is not adopted, then the process must start from scratch at 
a later date. All three sources of evidence (directional, meta-analysis, consensus) 
are separately considered, and all three must agree, or the guideline cannot be put 
forward. The inclusion of meta-analysis is quite stringent and different from most 
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other organizations. Dr. Connis explained that in anesthesiology outcomes are 
often more consistent and clear-cut than in other specialties, thereby facilitating 
the pooling of data. When meta-analysis cannot be completed, the resulting 
document will not be termed a guideline, but instead will be called a "practice 
advisory." 
Dr. Connis said that these guidelines take two to three years to develop 
and are a consuming undertaking. Time and cost estimates are very difficult to 
assess, especially as his section is working on two to three guidelines at one time. 
His very rough estimates assign production costs for each guideline in the 
neighborhood of $150,000-200,000. There are two full-time methodologists, a 
part time librarian, and various support staff working on these guidelines, but a 
tremendous number of hours are logged by the volunteer activities of the task 
force and other Committee members. The task force chairman alone probably 
spends over two hundred hours working on his group's topic. 
The ASA has no plans at this point to revamp its decision tree concerning 
when or how to update guidelines. 
COMMENTS 
While all guideline creators recognize the need to · update or reVIse 
guidelines, there really is no consensus regarding how to decide when such 
updates are required. Of those interviewed, only the AAP mandates definite 
scheduled updates, and they are having great difficulties with the increasing 
amount of work this entails. 
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Furthermore, only the ACC and ACP-ASIM have expressed methods for 
recognizing update necessity based on changes in published evidence. Expert 
guidance is generally relied upon to distinguish when revisions are warranted, but 
this expert opinion is quite insular to the publishing organization and original 
work groups. I discerned no set methodology for the selection or evaluation of 
such experts besides general networking or acknowledgment. Of course, in 
relatively small specialties (e.g. the 5,000 members of the AACE) a general 
agreement among members as to topic expertise probably does yield the 
appropriate personnel. However, to my knowledge, no group has seriously 
evaluated whether this type of expert enlistment does indeed capture an 
appropriate group of individuals or whether the overall knowledge base of such a 
group is diminished by a subjective and potentially biased method of selection. It 
should be noted that this difficulty also potentially plagues the guideline's actual 
update process, as expert opinion is requisite for the interpretation of the evidence 
accumulated after any literature or systematic review. 
Some form of systematic, albeit abbreviated or restricted, literature search 
might be used to supplement expert opinion when deciding whether new evidence 
recommends a guideline update. Other than the ACC and ASIM, the use of such a 
search has not really been considered. At the least, a study might distinguish 
whether adding such a literature search advises the decision to update in a 
different and/or more productive manner than just relying on previously called 
experts. 
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It is also clear from speaking with these persons that assigning accurate 
costs to guideline development or revision is virtually impossible. The estimates 
vary widely. This makes some sense because organizations all have different 
ideas and goals for their guidelines, and some topics and/or organization 
guidelines are more labor-intensive than others. However, cost considerations 
must be evaluated. Guideline revision is a continual and cyclical process, and 
therefore a continual drain on healthcare resources. If we are to judge whether 
guidelines and their required constant upkeep are a boon to healthcare, we must 
be able to balance their costs against what is potentially given up for them. 
Organizations should attempt to itemize the resources put forth in the guideline 
development or revision process. This might constitute another study. 
For all the resources expended on CPGs, there· have been only cursory 
attempts to quantify the degree to which this information is being disseminated 
and finally utilized by physicians, health agencies, and patients. There have been 
even fewer attempts to measure the effects or outcomes of CPGs on the practice 
of clinical medicine. This makes sense in that resources were initially focused on 
the construction and implementation of CPGs; however, the time has come to test 
these health care mechanisms. In my informal conversations, the lack of past 
efforts on this front was generally acknowledged. There is still uncertainty as to 
how to factually evaluate CPGs outcomes. Money is tight, so once again it is the 
larger organizations that are slowly undertaking the effort. The ASIM's Qnet 
project is setting up large scale cooperative outcome studies to evaluate guideline 
effects, and the ACC has recently started a division, Guidelines Applied in 
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Practice (GAP), whose chief function will be "scientifically" evaluating the 
implementation of guidelines and whether patient care is improved. 
It appeared that the larger the organization, the more thorough were its 
methods. The ASIM and ACC all have appreciable, if varying, efforts in place to 
review trends or new evidence on an ongoing basis. The AAP has scheduled 
updates. The ASA, while smaller, produces full-scale reviews including meta-
analysis. For all its efforts, the AACE, an IM subspecialty organization, was 
clearly the least systematic in process and review. With only 5,000 members and 
limited resources, the AACE accomplishes as much as it is able; and as a 
physician organization, its expertise certainly bolsters the production of quality 
guidelines. However, these observations should serve as a caution regarding the 
presumed general quality of CPGs. It would be interesting to renew this sort of 
evaluative study between larger physicians' organizations who have produced 
many guidelines and smaller doctor groups that have put out only a few. 
Likewise, a study could be undertaken to compare physician group CPG 
originators with either patient advocate groups or the insurance groups that 
produce guidelines. Are there differences in the methods employed by these 
groups? Are there differences in the final products? 
One of the most confusing update issues is the fine line between what 
constitutes an update and what constitutes the information gathering used to 
decide to update. The overlap between the two causes a redundancy of efforts and 
resources. A more fluid process of continual update may avoid this redundancy. 
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One possible algorithm demonstrating such a process is shown in Figure 
1. A systematic development process is initiated to create the CPG. The topic 
writing committee or panel would remain intact or integrate a proportional 
rotation of members (like the ACC). Personnel trained in methods would "sift" or 
comb through the literature on an ongoing basis (perhaps quarterly) with clearly 
defined search parameters that were developed in conjunction with the initial 
development panel or committee. Additional annual surveys sent to systematically 
selected experts would supplement this information. Evidence tables or 
summaries could be disseminated to the topic committee each quarter and 
discussed at annual meetings to decide whether to leave the CPG as is, to update it 
by pertinent recommendation, section, or background information, or to start the 
process over from scratch. Additionally, a formal review for the topic panel or 
committee would be required five years from the most recent full rewrite; 
essentially, an examination of the amassed evidence from the previous five years 
of"sifter" literature searches and expert testimony would occur. 
Problems seem to arise when long intervals stretch between evidence 
assessments. A greater accumulation of information complicates the appraisal of 
any evidence and increases the potential for redundancy between an update check 
and an actual update. This is especially true because a defined approach to 
updating has not been developed. Should an update be a re-development of the 
guideline, or can it be a piecemeal revision of the existing document? An ongoing 
information collection process incorporates updating; the information found goes 
straight into the update. 
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Even if piecemeal revision is incorporated via ongoing review, a five year 
assessment of the accumulated evidence is prudent to decide if the guideline 
should be rewritten in total. The guideline developers may lose sight of the forest 
by focusing on the trees. If new conceptualizations or medical practices have 
developed around or beyond the old topic, then the topic's foundation framework 
may have become irrelevant no matter how many piecemeal revisions have been 
made. The scheduled re-evaluation of the topic ameliorates this possibility 
without forcing a full-scale rewrite when it is not necessary. 
The "sifters"' or methodologists' collection of evidence could be conducted 
via searches for RCTs, or editorials, or commentaries, or expert opinion. It only 
needs to be established which method or combination of methods secures the best 
results. Studies to assess validity and reliability, and further develop these 
methods can be implemented by comparing updates or searches or expert 
selection for the same topics between different EPCs or other research groups. 
With the electronic resources now available, ongoing updating could 
easily be carried out to avoid more lengthy and costly processes. Changes in situ 
can be made continuously, as the ACC hopes to do with its "updates" (versus full 
"revisions"). With constant perusal and the constant resources of a tabled group of 
experts, the guideline would never get far behind the curve. The original idea to 
set "full" review dates at specified intervals for each CPG would then regain 
credibility as the guideline would retain its authority during the interim. 
The methods supporting and systematizing the development of clinical 
practice guidelines have evolved greatly over the last fifteen years. However, the 
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commitment to and study of guideline rev1ew, dissemination, and outcome 
evaluation has lagged. More research must be done in all three of these areas. 
Guideline review and update processes are gaining greater attention, but efforts 
need to be redoubled. Outdated guidelines are worse than no guidelines. Without 
further attention to this area of medicine, the promise of guidelines will not be 
realized, and, in fact, a potentially powerful means of improving patient care at 
the individual and societal levels may be undermined. 
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Appendix One 
Organizational Process For Developing A Clinical Practice Guideline 
I. TOPIC IDENTIFICATION 
• SecUon/CommUtee/CounciVfask Force 
Identifies a disease, condition, situation, 
or treatment (high risk: volume; 
dlagnosUc/lreatment varlab!lity; 
avallablU\y of evidence; potential of legal 
liability; posslblllty of outcome 
modification; cost; target audience, etc) 
XIV, REVISE THE 
CLINICAL PRACTICE 
GUIDELINE 
XIII. DISSEMINATE AND 
IMPLEMENT 
CLINICAL PRACTICE 
GUIDELINES 
II. DEVELOP INTENT 
FOR CLINICAL 
PRACTICE 
GUIDELINE 
XII. APPROVED BY 
AAP EXECUTIVE 
COMMITTEE 
XI. SEND TO BOARD 
OF DIRECTORS' 
REVIEWER 
.... 
Ill. APPROVAL OF 
INTENT 
. Steering Commlllee 
on Qua!Uy 
Improvement and 
Management 
. Standing Board 
approval of Intent 
X. SEND TO MEDICAL 
EDITOR 
IV.APPOINT ACADEMY 
SPECIALISTS, 
PRACTITIONERS, 
EPIDEMIOLOGISTS 
TO SUBCOMMITTEES 
. Sections, Committees, 
Offlce.based Pracl!tloners, 
Epidemiologists, outside 
medical or~anlzstlona 
IX. OUTSIDE 
ORGANIZATIONAL 
REVIEW 
V. BOARD OF 
DIRECTORS 
APPROVAL OF 
SUBCOMMITTEE 
MEMBERS VIA AAP 
EXECUTIVE 
COMMITTEE 
---- ---- -------------~-
VI. DEVELOP CLINICAL 
PRACTICE 
GUIDELINE 
•In-depth literature review 
•In-depth data 
ana!ysls/meta-analya!a 
• Spectftc recommendations 
VII.GATHER BASELINE 
DATA (optional) 
VIII. REVIEW DRAFT 
CLINICAL 
PRACTICE 
GUIDELINE 
AAP Section/Committee 
Reviews 
Steering Committee on 
Quartty Improvement 
and Management 
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I. DEFINE THE PROBLEM 
• Select topic• 
XV. REVISE THE 
CLINICAL PRACTICE 
GUIDELINE 
XIV. DISSEMINATE AND 
IMPLEMENT 
CLINICAL PRACTICE 
GUIDELINE 
XIII. DEVELOP CLINICAL 
PRACTICE GUIDELINE 
RECOMMENDATION 
Clinical Practice Guideline Methodology 
II. COMPARE 
INTERVENTION 
Deline: 
providers 
practice setting 
classic case 
~ 
--
Ill. IDENTIFY HEALTH 
OUTCOMES* 
Patient preferences 
Cost analysis 
Health outcome 
measures 
•Think backwards. St:1rt by Identifying: 
IV.DEVELOP 
STRUCTURE OF 
PROBLEM 
Evidence model 
Decision tree 
Algorithm 
I) health outcomes (length and quality of life; fuuctional disability, death, etc) 
!hat patients experience and care about; 
2) interventions; 
3) definition of the problem, etc. 
••Answer the question: 
Is this the best among the interventions, given the evidence, 
professional/clinical experience, cost, benefits, harms, etc, to achieve 
the specific health outcomes from the patient's perspective? 
Collect 
Baseline 
D•ta 
XII. SELECT THE XI. DEVELOP X. COMBINE THE IX. DEVELOP 
BEST BENEFITS AND EVIDENCE EVIDENCE 
ALTERNATIVE HARMS • Mela·analys!s TABLES 
STRATEGY** BALANCE SHEET and clinical • Sensillvity 
subjective analysis 
judgement . Decision 
analysis 
~ 
..... 
V. DEFINE RESEARCH 
QUESTIONS 
Critical linkages 
• Decision models 
VI.CONOUCT 
LITERATURE REVIEW 
KeyWords 
MeSH terms 
Inclusion Items 
VII.DEVELOPnMPLEMENT 
LITERATURE REVIEW 
FORMS 
VIII .ABSTRACT THE 
EVIDENCE FROM 
THE ARTICLES 
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Appendix Two 
AACE Standards on Medical Guidelines for Clinical Practice 
1. Purpose of the guideline is specified. 
2. 
3. 
4. 
5. 
A. The guideline format should be clear and user friendly. 
B. The guideline should indicate how it is the same and how it differs 
from other guidelines covering the same area. 
C. The guideline should include a strategy for ongoing distribution. 
Rationale and importance of the guideline are explained. 
A. A brief description of the review process that led to the 
development of the guideline should be given. 
B. The guideline should be specific enough so that it can be used in 
review articles as well as performance/quality measurements. 
The participants in the guideline development process and their areas 
of expertise are specified. 
A. Describe the process for selection of the authors and reviewers of 
the guideline. List the credentials of these authors and reviewers. 
Targeted health problem or technology is clearly defined. 
Target patient population is specified. 
6. Intended audience or users of the guideline are specified. 
7. The principal preventive, diagnostic, or therapeutic options available 
to clinician and patients are specified. 
8. The health outcomes are specified. 
A. The points of view put forth in the guideline must be supported by 
a scientific and clinical evidence and outcome data. The weight 
given to specific studies must be documented and the time frame of 
those studies must be indicated. 
B. The guideline must be comprehensive to the condition addressed 
and must include relevant outcomes of the interventions. For 
example, what is the likelihood of recurrence in a patient with a 
1 em capillary carcinoma of the thyroid if the patient has any 
hemithyroidectomy versus the total thyroidectomy. 
C. The guideline should indicate the outcome, which is the aim to be 
achieved in the application of the practice parameter (clinical 
condition). The outcome might include cure of the disease; 
delayed morbidity or mortality; symptomatic relief; improved 
quality of life; conservation of resources (prevention of antibiotic 
resistance, for example), impact on patient and physician 
behavior. 
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D. The guideline should indicate the measures used to determine 
those outcomes. For example, length of life, quality of life, length 
in the hospital, efficiency of control of overhead factors. 
9. The method by which the guideline underwent external review is 
specified. 
10. 
11. 
12. 
An expiration date or date of scheduled review is specified. 
A. The guideline should be reviewed and revised probably within five 
years or if new research findings emerge. 
B. The guideline should specify the planned review date. 
C. The guideline should indicate that a system is established to 
monitor the emergence of the information, which may necessitate 
revision. 
D. The guideline should include the methods to evaluate its own 
outcome performance and specifically to measure the guideline's 
impact and affect and indicate how this information will be used to 
revise the updated guideline. 
Method of identifying scientific evidence is specified. 
A. Explain the rationale for including or excluding studies related to 
the topic. 
B. Indicate in the methods used to evaluate the scientific literature 
and other research findings. Explain why articles are included or 
excluded. List all the articles included in the guideline. 
Time period from which evidence is reviewed is specified. 
A. The guideline literature review should be current within 3 to 5 
years. 
13. The evidence used is identified by citation and referenced. 
A. The guideline should be clearly referenced in a standard scientific 
paper format. 
14. Method of data extractions is specified. 
15. Method for grading or classifying the scientific evidence is specified. 
A. The guideline must indicate if the expert opinion given by the 
authors of the guidelines was linked to scientific evidence (to 
create their recommendations). 
B. The guideline can and should incorporate findings from review of 
the literature and from the clinical judgment of the authors of the 
guideline. The weight given to each type of finding should be 
described. 
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C. Outcome data, when available, should be published also and the 
process by which the particular outcome data were selected should 
be described. 
16. Formal methods of combining evidence or expert opinion are used 
and described. 
17. 
18. 
19. 
A. If the recommendation of the guideline authors differs from the 
data in the published literature, an explanation for this difference 
must be given. 
Benefits and harms of specific health practices are specified. 
A. The guideline should indicate the appropriateness of the 
recommendations in specific clinical circumstances. The absolute 
nature or flexibility of the recommendation should be indicated. 
For example, if there are different ways to treat a particular 
condition, the rationale the best treatment should be given and the 
rationale for the best alternative treatments should also be given. 
B. The guideline should provide the information (clinical, scientific, 
and economic) needed to make decisions. 
Benefits and harms are quantified. 
The effect on health care costs from specific health practices is 
specified. 
A. The guideline should be adaptable to different practice 
environments such as private offices. hospitals, clinics, and other 
health care facilities. 
B. Where appropriate economic data should be given. The method 
for collecting and evaluating these economic data should be 
described. For example, in the treatment of hyperthyroidism 
indicate the cost of radioiodine, surgery, and medication in 
different parts of the country and describe how this information 
was obtained. 
20. Costs are quantified. 
A. The guideline should note the cost of one procedure over another 
and indicate how that affects patient care and outcomes. 
21. The role of value judgements used by the guideline developers in 
making recommendations is discussed. 
22. The role of patient preference is discussed. 
A. Where appropriate the guideline should define and assess patient 
preference data. For example, two patients prefer one form of 
treatment of hyperthyroidism over another and if so explain why 
and whether this patient choice is compatible with good care and 
cost effectiveness. 
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B. The guideline should provide data regarding patient preference for 
one treatment over another and explain in the rationale for that 
preference (cultural, regional, alternative medicine approach). 
23. Recommendations are specific and apply to the stated goal of the 
guideline. 
A. Recommendations are graded according to the strength of the 
evidence. 
B. The guideline should clearly state limitations of the 
recommendations in the guideline and should state the process 
used to foimulate those limitations. 
25. Flexibility in the recommendations is specified. 
References 
1. 
2. 
Shaneyfelt T, Mayo-Smith M, Rothwangl J. Are Guidelines Following 
Guidelines? The Methodological Quality of Clinical Practice Guidelines 
in the Peer-Reviewed Medical Literature. JAMA. 1999; 281:1900-1905. 
American Medical Association, Office of Quality Assurance. Attributes 
to Guide the Development and Evaluation of Practice Parameters. 
Chicago, IL; American Medical Association; 1990. 
Page 4 of 4 
A:\Agency Querles\AACE\AACE Standards on Medical Guidelines.doc 
Approved by AACE Board July 1999 
Appendix Three 
Clinical Statements I Manual- Section I 
I of2 
wysiwyg://155/http://www.acc.orglclinical/manual/manual_I.htm 
Note: These documents are best viewed with Internet Explorer version 5.0 and 
higher or Netscape Navigator 6.0 and higher. 
Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/ AHA Task Force on Practice Guidelines 
Section 1: Overview of Methodology 
and Purpose of the Manual 
Importance of ACC/ AHA Guidelines 
• 
The creation of clinical practice guidelines h<;~s been a joint activity 
between the American College of Cardiology (ACC) and the 
American Heart Association (AHA) since the 1980s. The guidelines 
advance the missions of both organizations by providing clinical 
recommendations to health care providers for the purpose of 
improving cardiovascular health. The Institute of Medicine defines 
practice guidelines as, .. systematically developed statements to 
assist practitioner and patient decisions about appropriate health 
care for specific clinical circumstances ... (1990) Well developed 
guidelines have the potential to enhance the appropriateness of 
clinical practice, improve the quality of cardiovascular care, lead 
to better patient outcomes, improve cost-effectiveness, and 
identify areas of further research needs. 
Purpose and Scope of the Manual 
To continue as a leader in the field of clinical practice guidelines, 
the ACC/ AHA Task Force on Practice Guidelines (Task Force) has 
overseen the creation of this manual to assist guideline writing 
committees in navigating guideline creation. The bulk of this 
manual consists of tools to assist guideline writers in interpreting 
and applying the methodology. A flowchart highlighting the key 
steps in the development of evidence· based guidelines (Figure 1) 
serves as the basis for organizing the manual. 
The Task Force understands the challenges in applying a uniform 
methodology to guidelines that represent diverse diseases, 
conditions, diagnostics, and interventions. In all cases, writing 
group members should familiarize themselves thoroughly with the 
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manual, as these policies and standards provide the framework for 
guideline creation. However, if warranted the Task Force may 
allow exceptions to the written policies. 
Staff Support 
The ACC and AHA provide scientific and 
administrative staff to support the creation of 
evidence· based guidelines. A Research Analyst 
... 
Table -af Contents 
and Guideline Manager are assigned to each guideline to assist 
writers with the methodology and process of guideline 
development. 
Bock to top 
Page last updated 03/1212002 
4119/2002 3:24 PM 
L 
i 
' 
j 
Figure 1. Steps in the Development of Evidence-Based Guidelines ~· 
Step One 
Determine the guideline 
scope and clinical 
objectives 
t 
Step Two 
Define and conduct 
appropriate and comprehensive 
literature searches 
Step Three 
Sort and evaluate the 
evidence 
Step Four 
Synthesize and interpret 
the evidence 
Step Five 
Write recommendations 
based on expert interpretation 
of the evidence 
Step Six 
Assign classification of 
recommendations and 
strength of evidence 
Step Seven 
Create tables, diagrams, 
and mnemonics describing 
recommendations 
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Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines !" 
Section II: Tools and Methods for Creating 
Guidelines 
• Step One: Determine the Guideline Scope and Clinical 
Objectives 
Topic Selection 
I •• ]Tabl-e ot! Contents 
r 
ACC/ AHA clinical practice guidelines are written on three general categories: 
health conditions, procedures, and diagnostics. The Task Force determines the 
topics for guidelines and selects the writing committee members, while the writir l 
committee is responsible for developing the guideline's content. 
Determining the Guideline's Scope 
Before and during the first meeting, the writing committee primarily focuses on 
coming to consensus about the guideline's scope (see Checklist 1 ). Literature 
searching is conducted to determine the scope of the guideline, as appropriate 
(see Step Two). 
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A CCI AHA guidelines are usually intended to 
provide recommendations applicable in the 
United States; however some guidelines written 
in collaboration with the European Society of 
Cardiology or other partners have a broader 
target audience. The methodology for 
international guidelines is the same as national 
guidelines, with conclusions and 
recommendations based on expert judgement 
applied to clinical evidence. lnternational 
differences in disease management and health 
care resource availability may be noted when 
such differences might have significant impact on 
the implementation of recommendations. 
Although some guidelines also address issues of 
Ideally, a set of guidelines 
should give practitioners, 
patients, and policymakers 
an explicit description of the 
projected health benefits 
and the projected harms or 
risks. In addition, projected 
outcomes should be 
compared with those for 
alternative courses of care 
for the clinical condition in 
question. 
-Institute of Medicine, 1990 
cost-effectiveness and related economic analyses, ACC/ AHA guidelines are 
generally meant to provide clinically relevant information outside of the context< 
costs and reimbursement. If cost issues must be included, guideline writers should 
limit the scope to previously published analyses and not attempt to create any ne• 
economic analysis within the document. 
Guideline Updates and Revisions 
Maintaining guideline content that is up-to-date with the clinical evidence and be 
practices in the field of cardiology is an ongoing challenge. The Task Force is 
exploring new systems to update guideline content more regularly. In the 
meantime, all guidelines are reviewed for possible update within one year after 
publication. The research analyst and the chair monitor literature on the topic, 
and compare the current guideline recommendations against the latest data. The 
entire writing committee is periodically surveyed to determine if the guideline (or 
sections within the guideline) needs updating. Guideline updates should focus on 
substantive changes to recommendations rather than editorial changes to the 
document. Otherwise, aU methodology in this manual applies to updates and 
revisions. 
Guideline Structure 
Guideline writers are encouraged to define as precisely as pbssible the overall 
guideline structure at the early stages of guideline creation. The Task Force has 
provided standard guideline outlines for each guideline type (see Table 2). These 
outlines improve consistency across guidelines and facilitate the effectiveness of 
on-line searching of our guidelines. They provide a common structure while 
allowing for flexibility as the topic demands. Guideline writers should determine 1 
the outsets which "standard concepts" apply to their guideline, then proceed with 
creating detailed clinical objectives under each concept. The standard outlines ar 
not prescriptive, nor are they meant to encourage the creation of textbook-style 
guidelines. 
Identifying the Clinical Objectives 
The main goal of guideline creation is to develop recommendations that allow 
providers to understand the evidence on the topic and apply it to clinical practice 
As such, guideline writers should progress with specific clinical objectives in mind 
It may be very helpful at the outset to consider what kind of guidance the readers 
will expect in the completed document, such as: 
• The role of exercise testing in asymptomatic patients 
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• The use of inotropic agents in patients with end-stage heart failure 
• Managing mitral regurgitation medically versus surgically 
A comprehensive collection of clinical objectives should be created within each 
main concept addressed by the guideline outline_ These clinical objectives serve a 
the basis for literature searching and sorting, and later for the compilation of 
guideline recommendations. 
Checklist 1. Determining the Guideline Scope and Clinical Objectives 
Questions related to the guideline overall 
o What is the guideline's targeted health condition, procedure, or 
diagnostic? 
o What is the purpose of the guideline? 
o What is within the scope of the guideline? 
o What is outside the scope of the guideline? 
o What is the epidemiology of the topic? 
o Who are the guideline's intended users? 
o What is the target patient population to be addressed in the guideline? 
o How does the guideline relate to other existing ACC/ AHA guidelines? 
o Can a few flow diagrams summarize the guideline, or at least key 
sub-sections? 
Questions related to the guideline's clinical objectives 
o What are the important clinical objectives related to the guideline topic? 
o What sub-topics and related topics must be included in the guideline? 
o Are flow diagrams appropriate to these sub-topics and related topics? 
o What are the potential benefits and risks for individual patients 
associated with an intervention or procedure? 
o What amount of clinical flexibility is appropriate for the topic area? 
o What clinical options are available? 
o What topics have already been covered in existing ACC/ AHA guidelines? 
•• T-able of Contents 1!il Back to top 
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Table 2. Standard Guideline Outlines 
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Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines 
Section II: Tools and Methods for 
Creating Guidelines 
• Step Two: Define and Conduct 
Appropriate and Comprehensive Literature Searches 
Finding and Managing the Evidence 
Once the scope of the guideline has been determined, 
comprehensive searching of the published literature takes place. A 
key component of the ACC/ AHA guideline methodology is the 
creation of recommendations based on the entirety of the evidence 
currently available. The Institute of Medicine describes literature 
searching as the key step in developing valid guidelines. 
It has been estimated that over 2 million articles and more than 
17,000 biomedical books are published annually. The challenge of 
finding relevant articles among the millions is compounded by the 
availability of multiple electronic databases, all of which offer 
different but partially overlapping pools of information. 
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The current resources for 
ACC/ AHA guideline development 
allow for searching in MEDLINE 
(via PubMed), EMBASE, the 
Cochrane Library, and Best 
Evidence. The Research Analyst 
assigned to the guideline will 
manage a computerized database 
of all citations relevant to the 
guideline topic. The Research 
Analyst and Librarian conduct 
searches and forward relevant 
citations to the writers. 
Literature Search Methodology 
Because a guideline based on 
an incomplete or biased 
evaluation or the literature 
can lead to inappropriate 
recommendations, the search 
for relevant research should 
be comprehensive, research 
should be selected using 
explicit criteria, and the 
validity of the results should 
be judged in a rigorous and 
reproducible fashion. 
- Cook, 1997 
Figure 2 outlines the ACC/ AHA process for conducting 
comprehensive literature searches for the guidelines. Initial 
literature searching focuses on published meta-analyses and 
systematic reviews. If high quality, relevant, and up-to-date 
meta-analyses or systematic reviews are found, these articles allow 
writers to focus on critiquing and updating an existing review as 
opposed to creating one. For the majority of topics, literature 
searching also includes randomized clinical trials, and is expanded 
to non-randomized studies, case studies, and opinion documents 
until the evidence-base is sufficient for each clinical question 
identified in Step One. Each article should be critically evaluated 
as to quality and clinical limitations, as discussed in Step Three. 
Documentation of Searching 
All literature searching for guideline development must be 
documented by the searcher and stored at the ACC offices. This 
allows the chair and Research Analyst to construct the text of the 
guideline describing the literature search criteria, thereby allowing 
guideline users to assess the comprehensiveness of the searching. 
In addition to searches conducted by staff, writing committee 
members are welcome to conduct their own literature searches, 
including search criteria beyond what the ACC/ AHA resources are 
able to provide (see below: Standard Search Criteria for ACC/ AHA 
Guidelines). The documentation for all literature searches must be 
forwarded to the Research Analyst using the Template: Literature 
Searches for ACC/AHA Guidelines included in this section. 
Standard Search Criteria for ACC/ AHA Guidelines 
• Literature searching includes the following on-line 
databases: 
o MEDLINE/PubMed 
o EMBASE 
o Cochrane Library 
o Best Evidence 
• Searches are limited to English language. (Searches will be 
expanded to languages other than English on a case-by-case, 
as requested basis.) 
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• Searches are limited to human subjects. 
• In the case of a guideline update, searches are limited to the 
time period following the publication of the last version of 
the guideline. 
• In the case of a new guideline or full revision, no time limits 
on searches are imposed, unless the writing committee 
determines that a different time frame appropriate (for 
example, a guideline on a diagnostic that did not exist 
before a certain date). 
• Gender and age are not limited, except when a specific 
clinical objective applies only to a particular sex or age 
group. 
• Publication type is initially limited to meta-analyses and 
systematic reviews. Publication type is expanded on an 
as-needed basis to include randomized controlled trials, 
non-randomized studies, case studies, and opinion 
documents. 
• If an acceptable systematic review or meta-analysis is 
identified, searches to update it are typically limited to the 
time period following the search cut-off date reported in the 
review. 
• .. 
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Figure 2. Process for Conducting Comprehensive Literature Searches for Guidelines 
Guideline writer forwards 
search requests to 
Research Analyst 
Librarian searches for Librarian searches Librarian searches Librarian searches 
meta-analyses and for randomized for non-randomized for case studies and 
systematic reviews controlled trials studies opinion documents 
Research Analyst removes Research Analyst Research Analyst 
non-relevant articles and removes non-relevant removes non-relevant 
sotts relevant articles by articles and sorts mticles and sorts 
clinical question or relevant mticles by sub- relevant articles by sub-
objective topic/guideline section topic/guideline section 
Are there high quality, Are there high quality, Are there high quality, 
relevant, and up-to-date No relevant, and up-to-date No 
relevant, and up-to-date 
No 
meta-analyses or randomized controlled non-randomized studies 
systematic reviews that trials that answer the that answer the identified 
answer the identified identified questions? questions? 
questions? 
Yes Yes 
Yes 
Proceed to Step Three 
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Manual for ACC/AHA Guideline Writing Committees 
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Section II: Tools and Methods for Creating 
Guidelines 
Table of Contents 
• Step Three: Sort and Evaluate the Evidence 
Stages of Sorting Evidence 
After the literature search results have been imported into the computerized 
database managed at the ACC, the Research Analyst reviews the abstracts and 
removes non-relevant citations. At this step, only the article's title and abstract 
are assessed, so any article likely to be relevant to the guideline is maintained. 
Additionally, the Research Analyst sorts the abstracts to correspond with the 
specific clinical objectives identified in Step One. This initial sort creates a 
comprehensive set of potentially relevant studies. 
Although the Research Analyst does a preliminary 
level of sorting, the clinical expertise of writing 
committee members is necessary to make the 
final decision as to whether the article is a 
relevant piece of evidence that should be 
included in the development of a 
recommendation. This often requires review of 
the article's full text and critique of the research 
methodology employed. As necessary, the 
research analyst will provide the full text of all 
peer-reviewed, published: 
• Randomized controlled trials 
• Meta-analysis 
• Systematic reviews of evidence 
It is important to err on the 
side of over-inclusion 
because once a trial has been 
excluded from the selection 
process it is unlikely to be 
reconsidered. Questionable 
articles which are included at 
one stage can be excluded at 
a latter stage when more 
information on the study is 
available. 
- Mulrow, 1996 
• Diagnostic studies using comparison with a gold standard 
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Along with each full text article, the writer will receive Checklist 2, which asks 
the writer to make the final determination of the article's role within the 
guideline. Documentation of completed checklists will be maintained by the ACC i 
the methodology files for the guideline. The Appendix includes three articles fror 
the British Medical Journal and articles by Pogue and Lau that provide further 
information on evaluating the quality of published literature. 
Unpublished Data 
Guideline writers are frequently familiar with data from abstracts and late 
breaking trials that may impact the guideline's content. The results from 
unpublished data should not be considered except in few instances, should be no 
older than 2 years, and should be clearly stated to be unpublished data in the 
guideline text. Only trials presented at a major national or international scientific 
meeting are allowed, and may not be used to support any recommendation. When 
trial data are discussed, the text should clearly state that the data are 
preliminary. Additionally, guideline writers should obtain slides from the trial 
presentation, perform a detailed review, and ask the presenter of the trial for 
guidance, keeping in mind that the trial group has the prerogative to request that 
the information not be published in a guideline. 
Balancing Scientific Rigor with Feasibility 
The Cochrane Collaboration publishes perhaps the most rigorous and 
comprehensive guide to conducting systematic reviews of evidence, and their 
methodology has provided the basis for much of this manual. However, due to tim 
and economic constraints, some components of their methodology (such as 
creating and validating criteria for which articles to include, and removing the 
journal and author names from articles being reviewed) are beyond the scope of 
ACC/ AHA guideline development. 
A less resource-intensive, more feasible approach is to establish a few basic 
criteria (such as randomized controlled trials only or studies with at least six 
month follow-up) and be as inclusive and unbiased as possible. The Task Force 
recommends rigorous review of the articles used in evidence tables and 
meta-analyses-those articles that are most fundamental to the guideline 
recommendations. Documentation of why studies are included and excluded from 
consideration will provide additional scientific rigor to the document and will be 
published on the ACC web site as a component of the guideline methodology. The 
Research Analyst assigned to the guideline can and should be used in scoring the 
articles and synthesizing the evidence (Step Four) to ease the burden on the 
writing committee. 
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Checklist 2. Determining the Evidence·Based for 
Guideline Recommendations* 
Guideline writers are asked to consider the merits, quality, and generalizability 
of each article relevant to the clinical objective. This checklist should be 
completed only for articles from the peer-reviewed, published literature that 
are: 
o randomized controlled trials, 
o meta-analysis/systematic reviews, or 
o diagnostic studies using comparison with a gold standard. 
Article! Author: 
Please indicate one of the following conclusions about the article: 
__ Yes, this is a relatively high quality study that provides credible results 
and should be included in the evidence table and references that support the 
recommendation(s) for this clinical objective. 
__ No, this study is not of sufficient quality to be included in the evidence 
table, but Yes, this study contains some useful information about the clinical 
objective and should be maintained as a reference for the text accompanying 
the recommendation. 
__ No, this is a relatively poor study that should not be used in the evidence 
table or in the references for this clinical objective. 
__ No, this study is not directly relevant to the clinical objective 
Comments: 
• Our methodology for grading individual studies is a work in progress. We are currently pilot testing 
this checklist with a number of writing groups as well as investigating more detailed checklists for 
evaluating study quality. Please re-visit this site in the coming months for newer checklists . 
•• Table of Conf,ents 
Ill Back to top 
Page last updated 03 I 12/2002 
4/19/2002 3:29 PM 
L 
! l,_ _ 
Clinical Statements I Manual- Section II 
l of4 
wysiwyg:/ll79/http://www.acc.org/clinica1/manua1/manual_llstep4.htm 
Note: These documents are best viewed with Internet Explorer versi9n 5.0 and 
higher or Netscape Navigator 6.0 and higher. 
Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines 
Section II: Tools and Methods for Creating 
Guidelines 
• Step Four: Synthesize and Interpret the Evidence 
Guideline Authoring Template 
~~--­~ 
Table of Contents 
To improve the consistency of guideline content, both within and between 
guidelines, the Task Force has created a guideline authoring template. Guideline 
writers will receive one template for each clinical objective they are responsible 
for writing. The following is a brief introduction to using the template: 
• The fields for guideline, author, section name, and clinical objective will 
be completed by staff. 
• The evidence base field will consist of the articles gathered through the 
literature search and sorting (Steps Two and Three). Writers whose clinica 
objectives have a large evidence base may also receive full text articles or 
an evidence table along with the template. 
• There are four fields for recommendation, including a checklist for 
classification and level of evidence for each recommendation (more than 
four recommendations can be written). After reviewing the evidence base, 
the writer should create recommendations that answer the clinical 
objective. See Steps Five and Six for details on writing recommendations. 
• The text field is used for placing recommendations in context (see 
"Narrative synthesis of evidence" below). 
• The additional references field can be completed by a writer who 
references other sources than those provided in the evidence base field. 
• If the clinical objective has a diagram, table, or graphic associated with it 
it can be added or referenced in this field (see Step Seven). 
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Narrative Synthesis of Evidence 
Assessing how much 
heterogeneity exists among 
trials included in a review 
and assessing whether they 
should be combined make up 
one of the crucial steps in a 
systematic review. 
Summaries of evidence should generally be in 
tabular for, and not in the text of the guideline. 
Text should be reserved for qualifying or 
clarifying the recommendations. The Task Force 
prefers that clinical trial data and other evidence 
be displayed in an evidence table or included in 
meta-analysis. When multiple trials have yielded 
similar, non-controversial results (e.g., the use of 
aspirin post myocardial infarction), a single · Jadad, 1998 
sentence with appropriate references may 
suffice. Long, descriptive paragraphs of the methodology and findings of individua 
trials are discouraged. 
Visual Synthesis of Evidence 
Preparing an evidence table involves identifying and extracting the key data from 
the relevant studies. The Cochrane Collaboration recommends beginning by 
deciding what comparisons need to be made, then identifying the data elements 
necessary to make those comparisons. Salient data elements may include, but are 
not limited to, number of patients, morbidity, mortality, dose-response, 
sensitivity, specificity, p-values, confidence intervals, positive predictive value, 
negative predictive value, and relative risk. 
The next step is to prepare visual summaries of the results of the studies included 
in each comparison. The data are usually displayed in a table that allows the 
studies' designs and results to be easily compared. However, sometimes the data 
are better summarized in a bar chart or other graphic summary. Information 
presented graphically can replace the need for "text-heavy" sections of the 
guideline. Examples of visual synthesis of evidence from published ACC/ AHA 
guidelines include: 
• Acute Myocardial Infarction Guideline, Figure 7 
• Atrial Fibrillation Guideline, Figure 16 
• Chronic Stable Angina Guideline, Table 21 
Analytical Synthesis of Evidence 
Sometimes recommendations can confidently be written based on the organizatio1 
of evidence in tables or graphs. Other times, a further step is necessary; analyzin! 
the data statistically to get an estimate of the heterogeneity of the individual 
effect sizes, an estimate of the summary effect size, and a measure of its 
variance. Guideline writers generally rely upon meta-analytic methods to conduct 
such analyses. 
A detailed guide to the methods of meta-analysis is beyond the scope of this 
manual. However, ACC staff is available to assist writing committees in conductio 
meta-analysis for guidelines. 
Also recommended is the Cochrane Collaboration, which offers free on its web sit 
(www.cochrane.org) software called Review Manager 4.1. RevMan allows for entl) 
of the characteristics of studies and their findings, and the creation of comparisor 
tables. It can perform meta-analysis of the data entered, and present the results 
graphically. A comprehensive handbook for conducting systematic reviews that ca 
be printed from the same web site accompanies the software. 
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Use of Other Guidelines/ Authorities 
Guideline text, recommendations, and evidence tables may be replicated from 
previous ACC/ AHA guidelines and statements endorsed by both organizations (e.g. 
National Cholesterol Education Program). Consensus statements or guidelines 
developed by others and not endorsed by the AHA and ACC should not be cited or 
referenced unless absolutely necessary, as this implies endorsement on the part o 
the organizations. 
Discussing Pharmacotherapy in Guidelines 
The Task Force has provided a detailed list of policies on discussing 
pharmacotherapy in guidelines as Checklist 3. In addition, a pharmacologist will 
either be assigned to each guideline or will be used in a consulting role to review 
the guideline's pharmacotherapy discussions before publication. 
Investigational treatments or drugs that are not available for general use may be 
mentioned, but should be clearly described as such and not given Class I, lla, or Ill 
recommendations. The writing committee should decide whether to list them as 
Class Ill, or not to list them at all. The presence or absence of FDA or CMS approv1 
of a drug or device for a specific purpose should generally not be mentioned. The 
criteria used by regulatory authorities are frequently different, and the A CCI AHA 
process should be independent of these regulatory issues. 
In the case of international guidelines co-sponsored by the ACC/ AHA/ESC, it is 
understandable that rare occasions may require a discussion of international 
availability of certain medications. However, such content should be addressed 
from the perspective of the patient or indication, and not from a policy {i.e. drug 
approval) perspective. 
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Checklist 3. Discussing Pharmacotherapy in Guidelines 
o Use generic or chemical name not trade name 
• e.g., simvastatin, not Zocor 
o Use broadest and most generic name of class appropriate 
• e.g., cholesterol-lowering not '"statins'" 
o List classes of drugs or drugs within classes according to evidence-based 
rationale and state rationale 
• e.g., first-line, second-line or side effects or cost-effectiveness 
• If no evidence-based rationale, list alphabetically 
o List all drugs (or none) within class 
• Indicate whether each is approved for the indication(s) under 
discussion 
1111 e.g., statins for primary prevention 
• Indicate whether each has evidence for the indication(s) under 
discussion 
Ill e.g., llb/llla"s 
o Discuss evidence for or against '"class effect"" 
• e.g., issue raised by ramipril in HOPE study 
o When so-called ··alternative medicines·· are known to be widely used, 
discuss the evidence about them and the issues raised by their use 
• e.g., possible interactions 
o Avoid the use of symbols and abbreviations when discussing drug dosing 
and timing. 
• e.g., use ""micrograms·· or ··meg'" instead of '"Fg"" 
• The Institute for Safe Medication Practices has issued a drug error 
alert regarding some commonly used abbreviations 
o Whenever a guideline includes specific drug information, such sections of 
the guideline should be reviewed by a pharmacologist during peer 
review. 
•• 
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Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines 
Section II: Tools and Methods for Creating 
Guidelines •• 
• Step Five: Synthesize and Interpret the Evidence 
Recommendations: The Essence of Guidelines 
Steps One through Four describe the methodology of guideline development as we 
as meta-analysis and systematic review. Guideline development, unlike the other 
methodologies, goes beyond the compilation and analysis of data to include 
recommendations that guide clinical practice. Guideline writers are challenged 
with considering a vast array of evidence and creating clinically applicable and 
clear recommendations from it. 
As the evidence is considered, conclusions and 
recommendations naturally evolve. Whenever this 
occurs, the recommendation should be condensed 
into a sentence or two and separated from the 
text (see Step Six). The recommendations are the 
core guideline content, while the text enhances 
the recommendations by providing further 
descriptive information, such as exceptions to the 
recommendations and clinical options. 
If Step One determined that flow diagrams were 
appropriate, recommendations should be 
incorporated into the flow diagrams where 
appropriate (see Step Seven). 
It does not matter how much 
information you have or haw 
valid and relevant it is, it 
should always be modulated 
by the values and 
preferences of the decision 
makers and those who will be 
affected by the decisions ... 
In most cases, however, it 
will be unclear how much 
your anecdotal information, 
values and preferences 
should modulate the research 
evidence available. 
Because guidelines are increasingly serving as the 
basis for other ACC and AHA activities (such as - Jadad, 1998 
pocket guides, performance measures, data 
4119/2002 3:30PM 
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standards, and GAP Projects), recommendations should be stand alone text that 
are written in complete sentences with as much detail as possible. Guidelines are 
intended to be applied by health care providers in real world settings, so the 
recommendations should be practical, feasible, and clinically flexible, thus 
facilitating the translation and implementation of recommendations. 
Expert Interpretation of the Evidence 
ACC/ AHA clinical practice guidelines are written by cardiologists, other experts in 
the field of cardiology or cardiovascular research, and representatives from other 
organizations and specialties, when relevant. Their scientific and clinical expertis' 
is germane to the creation of guideline recommendations that are useful to a 
broad spectrum of health care practitioners. 
Despite all the evidence that may be available for writing the guideline, expert 
interpretation will always be necessary. Expert interpretation serves as a funnel 
through which evidence on multiple questions and clinical situations is combined, 
condensed, and formulated into recommendations. 
EVIDENCE 
• • 
••• 
• • 
• 
• • • 
~ >llllllllllllillllj~ .... RECOMMENDATION 
Unfortunately, most evidence falls into the ··gray zone" of uncertainty. The 
evidence from different trials may come to divergent conclusions, the evidence 
may only apply to specific sub·populations, the evidence may be from 
methodologically weak studies, or the evidence may simply be insufficient to mak 
a decision. Only in rare instances is there an abundance of evidence available thai 
leads directly to an indisputable recommendation. 
Writing guidelines and formulating recommendations are not simple tasks. The 
guideline writer is frequently in a dilemma as to whether to delay making a 
decision or come to a conclusion despite the h·oles in the evidence. Checklist 4 
(see below) in this section provides a list of qualities of guideline recommendatior 
to consider when writing the document. 
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Checklist 4. Writing Guideline Recommendations · 
o Write all recommendations in complete sentences. 
o Write separate recommendations that apply to specific clinical 
objectives. 
o Write recommendations that are practical in the real world setting. 
o Describe the patients to whom the recommendation applies. 
o Use unambiguous language and clearly defined terms when writing 
recommendations. 
o Write recommendations in terms of active/positive actions rather than 
passive/negative actions, e.g., Class I recommendation to perform a 
test/ give a treatment that is useful/ effective rather than a Class Ill 
recommendation not to perform/give it. 
o When there are areas of uncertainty or controversy include this 
information in the recommendation. 
o Quantify as much as possible benefits, harms, and timeframes. 
o Write recommendations that incorporate data on patient preferences, 
when applicable. 
o Specify sub-population variability and exceptions in the 
recommendations. List the exceptions whenever possible. 
o Include flexibility in applying the recommendations, where applicable. 
o Recommendations must be consistent with previous ACC/AHA 
guidelines, unless there is new evidence to justify a change. Both the 
new evidence and the change must be described in detail. 
•• l''ab!e of Contents 
Bock to !<>p 
Page last updated 03/12/2002 
4119/2002 3:30PM 
I 
f 
Clinical Statements I Manual- Section II 
1 of3 
wysiwyg://185/http://www.acc.or&'clinical/manual/manual_ Ilstep6.htm 
Note: These documents are best viewed with Internet Explorer version 5.0 and higl 
Netscape Navigator 6.0 and higher. 
Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines 
Section II: Tools and Methods for Creating Guidelines 
• Step Six: Assign Classification of Recommendations and Level of 
Evidence 
Once recommendations are written, a Classification of Recommendation and Leve 
Evidence grade must be assigned to each recommendation. Classification of 
Recommendations and Level of Evidence are as follows: 
Classification of Recommendations 
Class 1: 
Class II: 
Class Ill: 
Conditions for which there is evidence and/or general agreement t 
procedure or treatment is useful and effective. 
Conditions for which there is conflicting evidence and/or a diverge 
opinion about the usefulness/efficacy of a procedure or treatment. 
lla. Weight of evidence/opinion is in favor of usefulness/efficacy 
lib. Usefulness/efficacy is less well established by evidence/opiniot 
Conditions for which there is evidence and/ or general agreement t 
procedure/treatment is not useful/effective, and in some cases m1 
harmful. 
Level of Evidence 
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Clinical Statements I Manual- Section II 
2of3 
wysiwyg://185/http://www.acc.org/clinical/manual/manual_ llstep6.htm 
Level of Evidence A Data derived from multiple randomized clinical trials 
Level of Evidence B Data derived from a single randomized trial, or non-ranc 
studies 
Level of Evidence C Consensus opinion of experts 
Applying the Classifications and Levels 
Some writers prefer to assign the Classification of 
Recommendation and Level of Evidence when writing the 
recommendations, while others prefer to state the 
recommendation and assign the classification later after 
re-examining the data. Writers preferring the first method 
will conduct Steps Five and Six of the guideline 
methodology simultaneously. 
The Classification of Recommendations and Level of 
Evidence are considered by many to be the core of the 
guidelines. As such, they are among the most debated 
aspects of the guideline within the writing group. See the 
section on writing committee consensus development for 
guidance on coming to agreement on recommendations. 
Like the collection 
quality analysis of! 
data from an exper 
study, collection ar 
of the evidence for 
development allow 
conclusions (ie, gut• 
recommendations) 
developed in a man 
is supportable by tl 
(ie, scientific evide 
literature). 
- Heffner, 1998 
Any combination of Classification of Recommendation and Level of Evidence is pc 
Table 3, below). For example, a recommendation can have a Class I, even if it is I 
entirely on expert opinion and no research studies have ever been conducted on tl 
recommendation (Level C). Similarly, a Class lla or lib can be assigned a Level A if 
multiple randomized controlled trials coming to divergent conclusions. 
Assigning a Level of Evidence B or C should not be construed as implying that the 
recommendation is weak. Many important clinical questions addressed in the guid 
do not lend themselves to experimentation or have not yet been addressed by higl 
investigations. Even though randomized controlled trials may not be available, thE 
question may be so relevant that it would be delinquent to not include it in the gt 
Table 3. Applying Classification of Recommendations and Level of Evidence 
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I Class I I Class lla I Class lib 
Level A o Recommendation that o Recommendation in o Recommendation's o Recor 
procedure or treatment favor of treatment or usefUlness/efficacy tess procedt 
is useful/effective procedure being useful/ welt established not use-
effective maybe 
~ Sufficient evidence o Conflicting evidence 
from multiple o Conflicting evidence from multiple o Suffic 
randomized trials or from multiple randomized trials or multipl! 
meta-analyses randomized trials or meta-analyses or mete 
meta-analyses 
LeveiB o Recommendation that o Recommendation in o Recommendation's o Recor 
procedure or treatment favor of tre-atment or usefulness/efficacy less procedt 
is useful! effective procedure being useful! well established not use 
effective may be 
o Insufficient evidence o Conflicting evidence 
from single randomized o Conflicting evidence from single randomized o fnsuff 
trial or non-randomized from single randomized tliat or non-randomized from siT 
studies trial or non-randomized studies trial or 
studies studies ' j_ 
LeveiC o Recommendation that o Recommendation in o Recommendation's o Recor 
procedure or treatment favor of treatment or usefulness/efficacy less procedt 
is useful/effective procedure being usefutr well established not use 
effective may be 
o Only expert opinion, o Only diverging expert 
case studies, or o Only diverging expert opinion, case studies, or o Only~ 
standard-of-care opinion, case studies, or standard-of-care case stt 
standard-of-care standar 
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Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines 
Section II: Tools and Methods for 
Creating Guidelines ... 
Tabl-e uf Contents 
• Step Seven: Create Tables, Diagrams, and 
Mnemonics Describing Recommendations 
Once the evidence tables and 
recommendations have been 
created, guideline writers should 
look for ways to visually 
summarize the key points in 
tables, diagrams, and mnemonics. 
The flow diagrams identified in 
Step One should be considered 
again in light of the evidence 
collected and recommendations 
written. Frequently, the text 
and/or recommendations can be 
condensed into a clinical 
The broad mandate of most 
guidelines ensures that 
guideline documents tend to 
be longer and less formulaic 
than other articles ... [but] 
surveys reveal that clinicians 
prefer pocket cards, concise 
pamphlets, and journal 
article summaries. 
- Cook, 1999 
pathway, algorithm, or decision-tooL These visual summaries assist 
physicians in understanding and applying the best care for 
individual patients. Visual presentations should be: 
• Written in clear and unambiguous language. 
• Logically organized. 
• Easy to follow. 
• Specific about relevant populations and clinical 
circumstances. 
• Specific about which elements of care are appropriate, 
inappropriate, and equivocaL 
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The guideline users will expect the evidence to be presented as 
proof of the recommendations' quality. However, in clinical 
circumstances, the key points of how the evidence applies to 
patients are the take· home messages that must be clearly 
presented and easily accessible in the guideline. 
Examples of good tables, diagrams, and mnemonics, include: 
• Atrial Fibrillation Guideline, Figure 9 
• Chronic Stable Angina Guideline, Figure 5 
• Perioperative Evaluation Guideline, Figure 1 
Preparing the Guideline for the Pocket Guide .. ~ ~ 
Many of the ACC/ AHA guidelines are converted ~ ~ 
into a pocket guide version to facilitate 
Table of Contents implementation of the guideline, specifically at 
the point of care. The information in the pocket guide should flow 
directly from the full guideline; thus guideline writers are 
responsible for ensuring that the guideline lends itself to the 
pocket guide format. The Task Force recommends that each writing 
committee designate one writer who will be responsible for the 
pocket guide. 
'II Back to top 
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Manual for ACC/AHA Guideline Writing Committees 
Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines ' 
Section II: Tools and Methods for Creating 
Guidelines •• Tabla of Contani:s 
• Writing Committee Discussions and Consensus 
Development 
Referring back to Figure 1, writing committee 
discussions and consensus development is ongoing 
at all stages of guideline development. Since 
. ACC/ AHA guidelines are team-written documents, 
coming to agreement on the scope, clinical 
objectives, evidence tables, text, 
recommendations, and visual summaries occurs 
throughout document development. Sub-section 
writers often come to consensus through phone 
calls or e-mail exchanges of information, while 
the entire writing committee comes to consensus 
during the face-to-face meetings. 
The safeguards of a group 
process should be initiated so 
as to ensure that the 
consensus achieved by the 
guideline development 
experts would reflect the 
consensus of the larger group 
of experts on the topic 
around the world. 
- Heffner, 1998 
In evidence-based documents such as clinical practice guidelines, consensus 
development is often most important around topics that have no literature base. 
Writing groups are faced with the challenge of addressing an important clinical 
question despite a lack of data. The ACC/ AHA guideline development process 
allows for the incorporation of minority opinions within the document if consensw 
can not be reached. 
Finalizing the Document 
At the final stages of guideline development, writers should re-examine the 
original goals regarding the scope of the guideline, as identified in Step One. Any 
identified gaps should be filled or explained before the document is sent to peer 
review. The writing group will be asked to give formal approval of the document 
4/19/2002 3:31PM 
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both before peer review and after peer review edits have been incorporated. 
Checklist 5 (see below) is provided as a toot to conduct an internal review of the 
guideline recommendations at both of these junctions. 
Checklist 5. Reviewing Guideline Recommendations 
o Are the recommendations within the stated purpose and scope of the 
guideline? 
o Are all recommendations cited and referenced (either in the text or in 
the evidence table)? 
o Are all recommendations assigned a Classification of Recommendation 
and a Level of Evidence? 
o Are clinicalty important and feasible recommendations made? 
o Are areas of uncertainty and exceptions to the rule clearly identified? 
o Are evidence tables and appropriate text provided to support 
recommendations, where applicable? 
a Are recommendations and key clinical points displayed visualty, when 
possible? 
a Are the recommendations consistent with other ACC/ AHA guidelines and 
other documents on the same or related topics? 
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Introduction 
Clinical Efficacy Assessment Subcommittee's 
Miss ion Statement 
The mission of the Clinical Efficacy Assessment 
Subcommittee is to oversee the development of 
guidelines that will improve the practice of 
medicine. The Subcommittee will provide advice, 
assistance, and direction to the Education 
Committee and to the staff of .... Scientific Policy in 
the development and implementation of College 
guidelines .... The subcommittee will make 
recommendations: regarding appropriate clinical 
practices to be embodied in evidence-based 
guidelines; guidance on the appropriate use of 
these guidelines; development of new methods to 
enhance College guideline application to clinical 
practice; and identification of technology 
assessment issues pertinent to the College and 
internal medicine. 
ACP-ASIM has been producing clinical practice guidelines since 
1981. Guideline development started as a three-year grant 
called the Clinical Efficacy Assessment Project (CEAP). The 
Project was and still is carried out under the aegis of the Clinical 
Efficacy Assessment Subcommittee (CEAS). 
The College appoints CEAS committee members. These are 
internists with expertise in primary care, health care 
administration, and medical and health services research. The 
Subcommittee provides advice, assistance, and direction to the 
Education Committee and to the staff of Scientific Policy in the 
development and implementation of College guidelines. The 
Subcommittee makes recommendations regarding: 
• Clinical practices to be addressed by College guidelines; 
• Guidance on the appropriate use of these guidelines; 
• Development of new methods to enhance College 
guideline application to clinical practice; and 
• Identification of technology assessment issues pertinent 
to the College and internal medicine. 
The scope of CEAP guidelines has broadened and covers many 
aspects of internal medicine, such as screening for cancers and 
cholesterol, and preoperative cardiac evaluation. 
CEAP guidelines target internists, but they can be easily 
adapted for use by subspecialists, family practitioners, and other 
primary care providers. CEAP aims to help College members 
provide the best health care possible, based on the best 
available current evidence. Guidelines are not designed to 
replace clinical judgment, rather they are meant to be 
evidence-based tools for clinical decision making. 
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CEAP Process 
What is CEAP? 
In 1981, the Clinical Efficacy Assessment Project, or CEAP, 
began as a three-year grant The goals were: 
1. To assemble and review the clinical literature on a 
specified topic; 
2. To identify the best scientific papers; and 
3. To analyze, reformulate, and present such information so 
that practitioners can readily determine the usefulness of 
diagnostic tests, procedures, or treatments. 
The initial charge from CEAP was to evaluate medical 
advances. Early ACP guidelines addressed diagnostic tests and 
technologies. These guidelines focused on topics developed 
through surveys of the ACP membership and were chosen 
based on the interest of the internal medicine community. 
Because of CEAP's success, the program was given permanent 
status at ACP. 
Today, CEAP is administered by the Clinical Efficacy 
Assessment Subcommittee (CEAS) and by the staff of the 
Scientific Policy Department of the ACP-ASIM. 
How are ACP-ASIM Guidelines developed? 
If you thought that the ACP-ASIM Guidelines were produced "by 
a bunch of old guys sitting around a board room," you're not 
alone in this misperception. ACP-ASIM guidelines are produced 
through a team effort involving the Scientific Policy staff, the 
steering committee known as the Clinical Efficacy Assessment 
Subcommittee (CEAS), and expert scientific collaborators. 
How are topics chosen? 
Choosing a topic for a clinical practice guideline is the first step 
in the CEAP process. Evidence reports commissioned by the 
Agency for Health Care Policy and Research (AHCPR) and 
generated by Evidence-based Practice Centers are the basis of 
our guidelines. These comprehensive evidence reports are 
systematic literature reviews and are available to the public. 
Data gathering 
Systematic literature reviews follow a strict protocol, and each 
article is assessed using standardized scoring techniques. 
Randomized clinical trials are given the highest evidential weight 
followed by prospective and retrospective cohort studies and 
case-control studies. The weighting is assigned based on the 
type of study and its methodological strength. Gaps in 
knowledge are also identified. 
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The evidence is summarized as evidence tables, the data is 
analyzed, and a report synthesizing the evidence is written. This 
evidence report, along with consensus statements where there 
are gaps in the evidence, becomes the foundation for the 
College's background paper and evidence-based clinical 
practice guideline. 
Review 
Both the background paper and the guideline undergo a lengthy 
and thorough review process. These papers are first reviewed 
by CEAS, and then outside reviewers are invited to comment on 
the manuscripts. After CEAS approves the papers, they are sent 
to the committee that oversees CEAS, the Education 
Committee. 
Once the Education Committee approves the documents, they 
go for final approval as ACP-ASIM policy to the Board of 
Regents, the highest body of ACP-ASIM. Simultaneously, the 
Board of Governors, who represent members from all 50 states 
and territories as well as our international members, reviews the 
manuscripts. 
The goal is to provide clinicians with a clinical practice guideline 
based on the best evidence available; to make 
recommendations based on that evidence; to inform clinicians of 
when there is no evidence; and finally, to help them deliver the 
best health care possible. 
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AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE 
GUIDELINE DEVELOPMENT PROCESS 
I BACKGROUND AND DEFINITION 
In 1991, the American Psychiatric Association (APA), through 
its Assembly and Board of Trustees, embarked on the process 
of developing practice guidelines. Since its inception, the APA 
has generated, under many different formats, guidelines for 
psychiatric practice. "Practice guidelines" as defined by this 
project, however, are systematically developed documents 
appearing in a standardized format presenting patient care 
strategies to assist psychiatrists in clinical decision-making. 
Importantly, while guidelines may be used for a variety of 
purposes, their primary purpose is to assist psychiatrists in their 
care of patients. 
Both the American Medical Association (AMA) and the Institute 
of Medicine (10M) have sought to define the key features 
necessary to ensure that practice guidelines are of high quality. 
The AMA's attributes apply to the development process, 
stating that practice parameters/guidelines should: 1) be 
developed by or in conjunction with physician organizations, 2) 
explicitly describe the methodology and process used in their 
development, 3) assist practitioner and patient decisions about 
appropriate health care for specific clinical circumstances, 4) 
be based on current professional knowledge and reviewed and 
revised at regular intervals, and 5) be widely disseminated. 
The 10M's attributes are criteria for evaluating the finished 
product: validity, based on the strength of the evidence, expert 
judgement, and estimates of health and cost outcomes 
compared with alternative practices; reliability/ reproducibility; 
clinical applicability and flexibility; clarity; attention to 
multidisciplinary concerns; timely updates; and documentation. 
Taken together, these prescriptives have essentially set 
national standards for guideline efforts. 
II TOPIC SELECTION 
t-
American Psychiatric Association 
Practice Guideline Development Process 
Revised 1999 Page 2 
The APA Steering Committee on Practice Guidelines oversees 
the development of APA guidelines. The Steering Committee 
selects topics for practice guidelines according to the following 
criteria: 
a) 
b) 
c) 
d) 
e) 
degree of public importance (prevalence and 
seriousness) 
relevance to psychiatric practice 
availability of information and relevant data 
availability of work already done that would be 
useful in the development of a practice guideline 
an area in which increased psychiatric attention and 
involvement would be helpful for the field 
Ill CONTRIBUTORS 
APA practice guidelines are developed by a work group of 
psychiatrists in active clinical practice, including academicians 
or researchers who spend a significant percentage of their time 
in the clinical care of patients. Work group members are 
selected on the basis of their knowledge and experience in the 
topic area, their commitment to the integrity of the guideline 
development process as outlined by the AMA and 10M, and 
their representativeness of the diversity of American psychiatry. 
Work group members are asked to decline participation if they 
feel there are possible conflicts of interest or biases that could 
impact their ability to maintain scientific objectivity. The 
following statement appears in every practice guideline to 
clarify this point: 
Psychiatrists who are in active clinical practice have 
developed this practice guideline. In addition, some 
contributors are primarily involved in research or other 
academic endeavors. It is possible that through such 
activities, many contributors have received income 
related to treatments discussed in this Guideline. A 
number of mechanisms are in place to minimize the 
potential for producing biased recommendations due to 
t-
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conflicts of interest. Members of the APA as well as 
representatives from related fields have extensively 
reviewed the Guideline. Contributors and reviewers have 
all been asked to base their recommendations on an 
objective evaluation of the available evidence. Any 
contributor or reviewer who believes that he or she has a 
conflict of interest that may bias (or appear to bias) his or 
her work has been asked to notify the APA Office of 
Quality Improvement and Psychiatric Services. This 
potential bias is then discussed with the work group chair 
and the chair of the Steering Committee on Practice 
Guidelines. Further action depends on the assessment 
of the potential bias. 
The APA is listed as the "author" of practice guidelines, with 
individual contributions, and reviewers acknowledged. Final 
editorial responsibility for practice guidelines rests with the 
Steering Committee and the Office of Quality Improvement and 
Psychiatric Services. 
IV EVIDENCE BASE 
The evidence base for practice guidelines is derived from two 
sources--research studies and clinical consensus. Where gaps 
exist in the research data, evidence is derived from clinical 
consensus, obtained through extensive review of multiple drafts 
of each guideline (see section VI). Both research data and 
clinical consensus vary in their validity and reliability for 
different clinical situations; guidelines state explicitly the nature 
of the supporting evidence for specific recommendations so 
that readers can make their own judgements regarding the 
utility of the recommendations. The following coding system is 
used for this purpose: 
[A] Randomized clinical trial. A study of an intervention 
in which subjects are prospectively followed over 
time; there are treatment and control groups; 
subjects are randomly assigned to the two groups; 
and both the subjects and the investigators are 
American Psychiatric Association 
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"blind" to the assignments. 
[B] Clinical trial. A prospective study in which an 
intervention is made and the results of that 
intervention are tracked longitudinally, that does not 
meet standards for a randomized clinical trial. 
[C] Cohort or longitudinal study. A study in which 
subjects are prospectively followed over time 
without any specific intervention. 
[D] Case-control study. A study in which a group of 
patients is identified in the present and information 
about them is pursued retrospectively or backward 
in time. 
[E] Review with secondary data analysis. A structured 
analytic review of existing data, e.g., a meta-
analysis or a decision analysis. 
[F] Review. A qualitative review and discussion of 
previously published literature without a quantitative 
synthesis of the data. 
[G] Other. Opinion-like essays, case reports, and other 
reports not categorized above. 
The literature review process is explicitly described in the 
guideline, including statements concerning: 
a) basic search strategy (e.g., key words, time period 
covered, research methodologies considered, etc.) 
b) sources for identifying studies (e.g., review articles, 
texts, abstracting and indexing services, Index 
Medicus, Sciences Citations Index, computer 
search services, etc.) 
c) criteria for selecting publications (e.g., number of 
relevant publications identified, whether all were 
·reviewed, whether only prospective studies were 
selected, etc.) 
d) review methods (e.g., publications reviewed in their 
entirety, abstract review only) 
e) methods for cataloguing reported outcomes (e.g., 
study design, sample characteristics, relevant 
findings, etc.) 
L 
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The literature review will include other guidelines addressing 
the same topic, when available. Wherever possible, evidence 
tables are constructed to illustrate the data regarding risks and 
benefits for each treatment. In many cases, however, evidence 
tables are used only to assist in writing the text and do not 
appear in the guideline. 
V FORMAT 
Each practice guideline is presented in a standardized format, 
with variations as appropriate (e.g., a guideline about 
psychiatric evaluation or a procedure may vary from that about 
a specific illness). 
The outline for the Major Depressive Disorders revision and 
subsequent guidelines and revisions is as follows: 
PART A: Treatment Recommendations 
I. Executive Summary of Recommendations 
II. Formulation and Implementation of a Treatment 
Plan 
Ill. Specific Clinical Features Influencing the Treatment 
Plan 
PART B: Background Information and Review of 
Available Evidence 
IV. Disease Definition, Epidemiology, Natural History 
V. Review and Synthesis of Available Evidence 
PART C: Future Research Needs 
Reviewers and Reviewing Organizations 
References 
Section I provides an overview of the organization and scope of 
recommendations contained in subsequent sections, with each 
recommendation identified as falling into one of three 
L 
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categories of endorsement: 
[I] Recommended with substantial clinical confidence 
[II] Recommended with moderate clinical confidence 
[Ill] Options that may be recommended on the basis of 
individual circumstances 
Section II presents a synthesis of the information discussed in 
section V, directed at providing a framework for clinical decision 
making for the individual patient. 
Section Ill addresses psychiatric, general medical, and 
demographic factors influencing treatment, including 
comorbidities. Relevant ethnic, cross-cultural, social or 
extrinsic factors (e.g., cultural mores, family, support system, 
living situation, health care beliefs, etc.) which could potentially 
preclude or modify the practical application of guidelines and 
may play a role in health care decisions are emphasized. 
Section IV presents the characteristics of the illness using 
current DSM criteria. Differential diagnosis, appropriate 
diagnostic procedures, aspects of the epidemiology and natural 
history with important treatment implications, and issues 
concerning special patient characteristics are outlined in this 
section. 
Section V presents a review of the available data on all 
potential treatments, organized according to three broad 
categories: 1) psychiatric management, 2) psychosocial 
interventions, and 3) somatic interventions. For each 
treatment, this information is presented in a standard format: 
a) goals of treatment 
b) efficacy data 
c) side effects and safety 
d) implementation issues (e.g., patient selection, 
laboratory testing, dosing, frequency, duration) 
L 
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Part C identifies directions for further research. 
Immediately following the research directions is the list 
individuals and organizations that submitted substantive 
comments of guideline drafts. 
Lastly, all references cited in the published guideline are listed. 
VI REVIEW, DISSEMINATION, AND UPDATES 
Each practice guideline is extensively reviewed at multiple draft 
stages. Draft 1 is reviewed by the Steering Committee. 
Approximately fifty reviewers with expertise in the topic, 
representatives of approximately one hundred related 
organizations, the APA Assembly, District Branches, Joint 
Reference Committee, Board of Trustees, Council on Quality 
Improvement, other components related to the subject area, 
and any APA member by request, are given the opportunity to 
review and comment on each practice guideline prior to 
publication. 
The development process may be summarized as follows: 
Step 1: 
Step 2: 
Step 3: 
Step 4: 
The Steering Committee on Practice Guidelines 
selects a small number of individuals to serve as 
the work group chair and members. 
The work group chair and Office of Quality 
Improvement staff develop a preliminary outline, to 
be continuously revised and refined throughout 
subsequent steps in the development process. 
A literature search is conducted by APA and/or the 
work group. Relevant articles from the search are 
obtained, in abstract or in entirety. The work group 
reviews these articles, codes them for study design, 
and constructs evidence tables for each treatment. 
Draft 1 is written based upon evidence tables and 
L 
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outline. 
Draft 1 is circulated to the work group and Steering 
Committee for review and comment. 
Draft 2 is written based on comments received. 
Draft 2 is circulated to the work group, the Steering 
Committee, and approximately 50 reviewers with 
expertise in the subject area. 
Step 8: Draft 3 is written based on comments received. 
Step 9: Draft 3 is circulated to the work group, Steering 
Committee, 50 expert reviewers, the Board of 
Trustees, Assembly, Joint Reference Committee, 
Council on Quality Improvement, Council Chairs, 
Commission on Psychotherapy by Psychiatrists, 
Committee on Women, District Branches, individual 
members (open review available through District 
Branches), the American Journal of Psychiatry and 
100 representatives of related organizations. 
Step 10: Draft 4 is written based on comments received. 
Step 11: Draft 4 is submitted to the formal APA review and 
approval process (Council on Quality Improvement, 
Assembly, Board of Trustees). 
After development of draft 4, and prior to final approval, work 
group members develop continuing medical education (CME) 
questions based on information contained in the guideline. 
Questions will be used for PRITE exams, ABPN recertification 
exams, on-line CME, and in the practice guideline monograph 
published by the American Psychiatric Publishing Group, Inc. 
At the same time, individuals are identified to develop a 
corresponding quick reference guide and patient and family 
guide. Such individuals may include APA staff, work group 
L 
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members, and/or independent contractors. These items need 
only to meet the approval of the SCPG as the information 
contained in them comes from the board-approved practice 
guideline. 
After final approval by the Assembly and Board, each practice 
guideline will be widely disseminated. Guidelines will be made 
available to all psychiatrists in a variety of ways, including 
publication in the American Journal of Psychiatry. Each 
practice guideline will be revised at regular intervals to reflect 
new knowledge in the field. 
Practice Guideline Development Process: A Quick 
Guide 
What Is a Practice Guideline? 
The primary purpose of a practice guideline (PG) is to assist 
psychiatrists in clinical decision-making and patient care. 
The AMA and the IOM have described the following attributes of good 
PGs: 
• Explicit methodology and development process 
• Systematic, meticulous review and documentation of evidence 
• Clear, unambiguous recommendations accompanied by 
descriptions of the strength of evidence behind them 
• Regular scheduled review and revision 
• Wide dissemination 
Overview of Steps in the Development Process 
A. Formation of the Work Group 
• The APA Steering Committee on Practice Guidelines (SCPG) 
identifies a disorder (or topic) as appropriate for a new guideline (or 
identifies the need for revision of a previous guideline). 
• The work group (WG) chair and members are selected. 
• An initial outline for the PG is established that 
o follows general format for all guidelines (table 1 and pp. 
2-4), 
o incorporates unique aspects of the specific topic of the 
PG. 
• Specific topic areas are assigned to individual WG members. 
B. Review of Evidence 
• A systematic literature search identifies relevant published studies. 
• Search results are distributed to WG members according to 
assigned topic. 
• WG members review specific articles and generate evidence tables 
that 
o show key elements and findings of each study, 
o serve as a focal point for discussion and development of 
treatment recommendations. 
C. Draft Creation and Review 
• An initial draft is written that is based upon 
o review and synthesis of available evidence, 
o consensus recommendations where evidence is lacking 
on clinically important issues. 
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• Multiple stages of review are undertaken, and reviewer comments 
are incorporated into each successive draft (table 2). 
• The PG is approved by the APA Assembly and Board of Trustees. 
D. Dissemination 
• Dissemination of the PG to practitioners is achieved through 
multiple mechanisms including publication in theAmerican Journal 
of Psychiatry. 
• Additional products are derived from the PG, including a quick 
reference guide and a continuing medical education program. 
Throughout the development process, consideration must be given 
to neutralize or balance against potential sources of bias or conflict 
of interest. 
Step-by-Step Process to Create Draft 1 
1. A systematic literature search identifies relevant published 
studies. 
• APA staff perform an initial PubMed search of relevant MeSH 
subject headings. 
• More specific, subsequent searches are performed on an as-
needed basis using specialized databases and/or additional key 
words. 
• The time period of interest will vary (searches are more extensive 
for new guidelines than for revisions). 
• lfWG members do any searches independently, APA project staff 
should be given information on the search parameters and output. 
2. The WG reviews and abstracts the evidence into "evidence 
tables." 
• Evidence tables serve as the essential building blocks of the PG. 
• Tables are constructed for all relevant prospective randomized 
clinical trials. 
• Tables are generally constructed for other relevant clinical trials, 
case-control studies, and cohort or longitudinal studies. 
• Each table summarizes key elements of a study including: 
o Description of study design 
o Categorization of study design (table 3) 
o Sample characteristics 
o Relevant findings (expressed in terms of defined 
outcome measures whenever possible) 
o Methodological strengths and limitations 
o Other factors that may impact on interpretation of study 
findings 
o Clinical implication(s) of the study 
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3. The WG discusses evidence tables at regularly scheduled 
conference calls. 
The purpose of discussion is as follows: 
• Review evidence tables. 
o Evidence tables are presented by individual WG 
members according to general subtopic. 
o Discussion should address the specifics of each study as 
summarized in the tables. 
• Draw conclusions about the clinical implications of the aggregate 
evidence on a particular subtopic. 
• Arrive at consensus recommendations on related issues that are 
clinically important but for which evidence is lacking. 
As stressed by AMA and I OM, it is critical that the evidence review 
drive the writing of the guideline recommendations, not the other way 
around. Structured discussions of the evidence by the WG in 
conference calls will naturally lead to the next step of the development 
process, writing an initial draft of the guideline. 
4. WG members write "summary statements" for their assigned PG 
sections. 
These statements summarize the evidence and the recommendations 
agreed upon. Combined, the statements form what will become Part B, 
Section V, of the guideline, "Review and Synthesis of Available 
Evidence" (table 1 ). 
Standard Sections of the PG, in the Order They Are Written 
1. Review and Synthesis of Available Evidence 
• Constitutes Part B, Section V, of the PG, but is the first section of 
the PG to be developed. Conclusions in this section serve as the 
basis for the recommendations of Part A, Section I, of the final PG. 
• Explicitly states the nature of the evidence supporting specific 
recommendations. 
• Permits readers to make their own judgments about 
recommendations. 
• Organized according to three broad categories: 
o Psychiatric management 
o Psychosocial interventions (e.g., individual, family, and 
group psychotherapies; cognitive, behavioral, and 
psychodynamic psychotherapies, psychoeducation, 
psychosocial interventions) 
o Somatic interventions (e.g., pharmacotherapy, ECT) 
• For each potential treatment, information is specifically presented 
on 
o goals of treatment; 
o efficacy data; 
p. 3 of 7 
L 
l_ 
o side effects and safety; and 
o implementation issues (e.g., patient selection; laboratory 
testing; treatment dosing, frequency, and duration). 
• For each aspect of treatment, this section includes 
o initial sentence that provides an overview of the available 
studies, 
o several sentence summaries of each of the 
methodologically rigorous studies (generated from 
evidence tables). 
• A concluding sentence/paragraph 
o describes the overall clinical implications of the evidence, 
o serves as the basis for an evidence-based treatment 
recommendation for Part A, Section I. 
2. Formulation and Implementation of a Treatment Plan 
• Constitutes Part A, Section II, of the PG. 
• Addresses general features of psychiatric management such as the 
following: 
o Performing a diagnostic evaluation 
o Evaluating the safety of the patient and others 
o Determining a treatment setting 
o Establishing and maintaining a therapeutic alliance 
o Monitoring treatment response 
o Providing education to the patient and to the family 
o Enhancing adherence to treatment 
o Evaluating and managing functional impairments 
• Addresses specific features of management such as the following: 
o Goals of treatment 
o Choice of initial treatment modality 
o Approaches for patients who do not respond to treatment 
initially 
• Formal evidence tables are not needed but appropriate references 
to the literature should be included and categorized (table 3). 
3. Specific Clinical Features Influencing the Treatment Plan 
• Constitutes Part A. Section Ill. of the PG 
• Addresses specific factors that may modify guideline application 
including: 
o Psychiatric factors (e.g. suicidality, violence or specific 
psychiatric symptoms or comorbidities) 
o General medical factors 
o Demographic factors influencing treatment (e.g. age, 
gender) 
o Ethnic and cross-cultural factors 
o Social or extrinsic factors (e.g., cultural mores, family, 
support system, living situation, health care beliefs, etc.) 
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• Formal evidence tables are not needed but appropriate references 
to the literature should be included and categorized (see table 3). 
4. Disease Definition, Epidemiology, Natural History 
• Constitutes Part B, Section IV, of the PG. 
• Provides clinically relevant background information about the 
disorder. 
• Includes brief discussion of the following: 
o Characteristics of the illness using current DSM criteria 
o Differential diagnosis and appropriate diagnostic 
procedures 
o Epidemiology and natural history 
o Issues concerning special patient characteristics 
• Formal evidence tables are not needed for this section, but 
appropriate references to the literature should be included and 
categorized (see table 3). 
5. Executive Summary of Recommendations 
• Constitutes Part A, Section 1, of the PG. 
• Usually written for draft 2 or 3. 
• Includes a very brief summary of the key points of psychiatric 
management 
• Consists primarily of the key treatment recommendations noted in 
the review of the available evidence. 
• Rates the strength of each recommendation (table 4) 
6. Future Research Needs 
• Constitutes PART C of the PG. 
• Usually written for draft 4. 
• Delineates key clinical questions for which evidence is lacking (and 
that will have been identified throughout the PG development 
process). 
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I. 
II. 
Ill. 
PART B 
IV. 
v. 
PARTC 
Draft 
1 
2 
3 
4 
Table 1 
General Outline for Practice Guidelines 
Treatment Recommendations 
Executive Summary of Recommendations 
Formulation and Implementation of a Treatment Plan 
Specific Clinical Features Influencing the Treatment Plan 
Background Information and Review of Available Evidence 
Disease Definition, Epidemiology, Natural History 
Review and Synthesis of Available Evidence 
Future Research Needs 
List of Reviewers and Reviewing Organizations 
References 
Table 2 
Practice Guideline Draft Review Process 
Reviewers 
WG, SCPG 
WG, SCPG, -50 reviewers with expertise in the subject area 
WG, SCPG, -50 expert reviewers, -100 representatives of related 
organizations, the APA Board of Trustees, Assembly, Joint Reference 
Committee, Council on Quality Improvement, Council Chairs, Commission 
on Psychotherapy by Psychiatrists, Committee on Women, District 
BranchExecutives, individual APA members (open review available through 
District Branches), and the American Journal of Psychiatry. 
Final review through the formal APA review and approval process (i.e., 
Council on Quality Improvement, Assembly, Joint Reference Committee, 
Board ofT rustees) 
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A Randomized clinical trial 
B Clinical trial 
C Cohort or longitudinal study 
D Case-control study 
E Review with secondary data 
analysis 
F Review 
G Other 
Table 3 
A study of an intervention in which subjects are 
prospectively followed over time; there are 
treatment and control groups; subjects are 
randomly assigned to the two groups; and both 
the subjects and the investigators are "blind" to 
the assignments. 
A prospective study in which an intervention is 
made and the results of that intervention are 
tracked longitudinally, that does not meet 
standards for a randomized clinical trial. 
A study in which subjects are prospectively 
followed over time without any specific 
intervention. 
A study in which a group of patients is 
identified in the present and information about 
them is pursued retrospectively or backward in 
time. 
A structured analytic review of existing data, 
e.g., a meta-analysis or a decision analysis. 
A qualitative review and discussion of 
previously published literature without a 
quantitative synthesis of the data. 
Opinion-like essays, case reports, and other 
reports not categorized above. 
Categorization of Study Designs and Nature of Supporting Literature 
Table 4 
Ratings of the Strength of Treatment Recommendations 
[I] Recommended with substantial clinical confidence 
[II] Recommended with moderate clinical confidence 
[Ill] Options that may be recommended on the basis of individual circumstances 
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Abstract 
Practice guidelines are rapidly becoming preferred decision-making resources in medicine, as ad-
vances in technology and pharmaceutics continue to expand, An evidence-based approach to the 
development of practice guidelines serves to anchor healthcare policy to scientific documentation, 
and in conjunction with practitioner opinion can provide a powerful and practical clinical tooL Three 
sources of information are essential to an evidence-based approach: a) an exhaustive literature syn-
thesis; b) meta-analysis; and c) consensus opinion. The systematic merging of evidence from these 
sources offers healthcare providers a scientifically supportable document that is flexible enough to 
deal with clinically complex problems. Evidence-based practice guidelines, in conjunction with practice 
standards and practice advisories, are invaluable resources for clinical decision making. The judicious 
use of these documents by practitioners will serve to improve the efficiency and safety of health care 
welL 
Keywords: Practice guidelines, Evidence-based medicine 
Practice guidelines in medicine have traditionally been created as policy documents that 
serve as information resources for the systematization of clinical pracdce. Their intended 
purpose is to provide physicians and other healthcare professionals with a useful reference 
for optimizing patient care. Because guidelines are usually developed and endorsed by 
a healthcare organization with the intent of regulating or standardizing clinical decision 
making ( 4;6), the broadest possible base of evidence is critical to their development. A 
broad evidence base will include a comprehensive assessment of peer-reviewed scientific 
literature combined with interpretations based on the clinical experience of practitioners 
(27). 
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Historically, the use of scientific literature in the development of practice guidelines has 
been selective rather than systematic. Prior to the 1980s, literature reviews were typically 
narrative, with the search process driven by the subjective judgment of reviewers (20;25). 
This "traditional" approach to literature review is often limited by the reviewers' knowledge 
of the literature and inclusion of a disproportionate number of articles supportive of the 
reviewers' viewpoints (8;18). According to Chalmers and Lau (3). 
Too often, authors of traditional review articles decide what they would like to establish as the truth 
either before starting the review process or after reading a few persuasive articles. They then proceed 
to defend their conclusions by citing all the evidence they can find. The opportunity for a biased 
presentation is enormous, and its readers are vulnerable because they have no opportunity to examine 
the possibilities of biases in the review. 
Evidence-based approaches have the potential to avoid systematic bias through the 
combination of a structured, exhaustive evaluation of scientific documentation and an as-
sessment of diverse practitioner opinion (5). The application of quantitative techniques and 
precise niles to combine research findings from various independent studies bolsters the 
scientific rigor of the aggregated literature with meta-analysis as the primary approach. 
However, it is important to note that meta-analytic results alone can be misinterpreted as 
easily as the results of an individual study. An evaluation of scientific documentation in 
the appropriate clinical context is aided by surveys and other documented opinions from 
experts and practicing healthcare providers. 
In applying meta-analytic and other scientific findings, the information provided by 
the practice guideline in the form of recommendations needs to be flexible enough to 
accommodate the complexities of clinical practice. Analytic evidence may indicate that a 
treatment or other intervention is effective. However, a guideline recommendation needs to 
allow for the clinical judgment of the practitioner, who determines whether the intervention 
is medically warranted or appropriate for a specific case. An additional source of evidence 
is needed in developing a guideline, and is best obtained by evaluating information based 
on the clinical experiences of experts and practitioners. Scientific knowledge can then 
be meaningfully combined with clinical judgment to develop recommendations for the 
application of a designated intervention (28). A guideline must also be feasible for use in a 
wide range of practice settings, meaning that scientific evidence and expert opinion should 
be supplemented by opinions from the broader population of practitioners (27). This broad 
base of opinion can benefit the development and implementation of a guideline in two ways. 
First, input from a variety of practice settings (e.g., large academic institutions and small 
rural settings) may contribute to a guideline's flexibility by identifying issues and problems 
unique to each distinct setting. Second, constructive forums for the expression of divergent 
opinions prior to a guideline's formal implementation enhance a guideline's acceptance by 
the general membership of a medical specialty. 
The purpose of this paper is to define and describe elements of a multifaceted guide-
line development process currently used by the professional association of one medical 
specialty, the American Society of Anesthesiologists (ASA). The ASA has published 
10 evidence-based practice guidelines, including guidelines for difficult airway manage-
ment, acute pain, chronic pain, cancer pain, preoperative fasting, and obstetrical anesthesia 
(2;7;9;1 0; 13;14; 19;21 ;23;24). These guidelines have been well received. 
Practice guidelines were developed by the ASA to address issues that could not be 
reasonably addressed by practice standards. Practice standards typically provide specific 
requirements for practice and are applied, with few exceptions, to virtually all relevant 
clinical situations. Although standards are important prescriptions for anesthesia care, it was 
recognized that more complex topics warranted a less rigid approach. Practice guidelines 
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were recognized as tools for providing clinical recommendations that would address these 
broader topics. Because of the complexity of the issues addressed, it was necessary for 
guidelines to incorporate a comprehensive array of evidence, including detailed assessments 
of the scientific literature and consensus documentation from multiple sources. 
IDENTIFICATION OF GOALS AND OBJECTIVES 
ASA' s evidence-based guidelines generally take 1-3 years to develop, and include a num-
ber of important steps before final completion and approval (Table 1). Typically a policy 
committee or task force is convened, consisting of academic and clinical practitioners 
recognized as experts in the topic of concern and representing a variety of practices and 
Table 1. Protocol for Practice Guideline Development 
l. Committee/task force assignment 
2. Identificatiop of potential evidence linkages 
3. Literature search 
a. Articles considered (original studies or reports published in peer-reviewed journals) 
1) Randomized controlled trials 
2) Nonrandomized comparative studies 
3) Controlled observational studies 
4) Retrospective comparative studies 
5) Uncontrolled observational studies 
6) Case reports 
b. Articles not considered 
1) Letters with no original data 
2) Editorials, review articles, and commentaries 
3) Meta-analytic studies (these analyses use data generated from other studies) 
4) Personal correspondence 
5) Unpublished papers/presentations 
4. Availability of scientific evidence in the literature is determined. If none of the evidence linkages 
has sufficient literature at this point in the process, a decision is made to either revise the evidence 
linkages or produce a practice advisory. 
5. Literature synthesis with assessment of directional evidence 
a. Review and sort studies into potential evidence linkage categories 
I) Record relevant information related to clinical factors (e.g., patient health status. clinical 
interventions used, health outcomes). 
2) Code information related to statistical evidence (e.g., study design, statistical tests. 
significance levels) 
b. Assign directional support for a potential evidence linkage addressed by each selected study 
(some studies address multiple linkages). For each study, determine direction related to patient 
benefit (positive, negative, or neutral). 
c. Determine overall direction of support for evidence linkage by summation of individual studies. 
6. Hypothesis development 
a. Assess overall linkage directions. 
b. Determine one-tailed hypotheses based on linkage direction. 
7. fvfeta-analysis: Adequately designed studies with sufficient quantitative information to describe a 
statistical relationship between a clinical intervention and a clinical outcome are idemified. 
a. Randomized controlled trials 
b. Nonrandomized comparative studies (conditionally acceptable) 
8. Consensus assessment 
a. Surveys related to evidence linkages 
I) Expert consultants 
2) Broad representation of practitioners 
b. Feasibility surveys 
c. Open forum presentations 
d. Internet commentary 
9. Formal review and approval by specialty organization 
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geographic areas. This broad representation leads to improved chances of generalizing the 
final recommendations. 
The task force begins the process by formalizing the intended topics. goals, and objec-
tives for the proposed guideline. These items include a description of the clinical disorders 
and conditions to be addressed by the guidelines, the types of patients for whom the guide-
lines are intended, clinical interventions (e.g., diagnostic tests, treatments) that will be 
considered in developing the guidelines, the principal intended users of the guidelines, and 
the practice settings in which the guidelines are applicable. These formalized topics play a 
crucial role in defining the scope of the guideline. Once the formalized topics, goals, and 
objectives are identified and agreed upon by the task force, an evidence model is formulated. 
The evidence model specifies criteria for inclusion/exclusion of data from the literature or 
other sources. 
DEVELOPING AN EVIDENCE MODEL 
Following specification of the guideline's goals and objectives, a series of potential evidence 
linkages is formulated (26). Evidence linkages represent statements about relationships be-
tween clinical interventions and clinical outcomes. A clinical intervention is typically an 
activity performed by a physician or other healthcare provider (e.g., administering a spec-
ified drug). A clinical outcome is recorded in terms of its potential benefit to the patient 
(e.g., reduced pain or minimization of specified side effects). An important component of an 
evidence linkage is the specificity of the identified interventions and outcomes. For exam-
ple, "analgesics provide maternal pain relief' would be further specified with a statement 
such as "epidural bupivacaine with opioids affects maternal analgesia during labor." This 
specification of targeted interventions and outcomes, in conjunction with other elements 
from the evidence model (e.g., intended providers, targeted patient population), will provide 
definitive direction for obtaining, organizing, and evaluating the evidence. 
This evidence model provides the framework for a guideline's clinical recommenda-
tions, and essentially provides the structure for the entire development process. Once the 
model is in place, the task force can initiate a multistep process. The elements of this process 
will include literature searches, literature syntheses, meta-analyses, survey development, 
consensus evaluation, feasibility studies, open-forum presentations, Internet commentary, 
and formal endorsement by the society or healthcare organization. 
LITERATURE SEARCH FOR EVIDENCE 
The literature search usually includes a computerized search oflarge reference sources, such 
as the National Library ofMedicine or Nursing and Allied Health Abstracts. Other electronic 
resources, also readily available on CD-ROM and/or the Internet, contain databases of 
reviews and abstracts as well as full-text articles. Software for bibliographic reference 
databases is an important tool in the search process, citation management, and dissemination 
of findings. Manual searches of literature are conducted to supplement electronic sources. 
Since electronic searches are typically driven by keyword search engines, they do not always 
have appropriate search mechanisms to locate relevant topics of interest. 
To be useful for evidence-based guideline development, studies must meet certain cri-
teria. First, a study must report a clinical finding or set of findings that can be tallied or 
quantified. This requirement eliminates reports that contain only commentary or undocu-
mented opinions of the authors. Second, a study must be an original investigation or report 
containing a clinical finding or set of findings. Thus, review m1icles or manuscripts that 
report findings from other sources are not used. For meta-analytic evidence, study findings 
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must clearly indicate a specified relationship between a clinical intervention and an outcome 
of interest. 
After the first phase of article search and classification is completed, a listing of all 
articles located to date is presented to the task force. Members are asked to review all articles 
listed, both those accepted and those not accepted, and to suggest changes in the acceptance 
or nonacceptance of individual articles when needed. They also may add articles not listed, 
to refine and expand the search process. 
Some practice guidelines developed by other organizations may include unpublished 
literature as potential evidence assessment. Use of such literature addresses the issue of 
sampling or "publication" bias, in which journals may be biased toward accepting articles 
that report statistically significant findings (25). As a result of such bias, many manuscripts 
reporting nonsignificant findings or no differences between groups or conditions are not 
accepted for publication. Often, upon discovering that they have no significant findings, 
investigators may not bother to submit a manuscript for publication (i.e., a "file-drawer" 
problem) (15). 
Although publication bias is a viable concern, ASA investigators do not currently use 
unpublished literature as a source of data for several reasons. Unpublished studies are not 
peer-reviewed and the use of such literature may incorporate data derived from inadequate 
research methods, the use of inappropriate or flawed statistical procedures, and other prob-
lems usually identified and corrected by the peer-review process. In addition, investigators 
do not know whether the obtained sample of unpublished studies is representative of the 
relevant population of unpublished literature. Therefore, this potential for selection bias is as 
serious a threat as that of publication bias. Although some research groups have endeavored 
to create repositories of uupublished studies, the completeness of such databases remains 
questionable. In lieu of obtaining a representative sample of unpublished studies, standard 
statistical methods (e.g., computation of a "fail-safe" N value) are available and provide 
a reasonable estimate of the required number of additional (i.e., unpublished) studies re-
porting contradictory outcomes sufficient to nullify the findings obtained from published 
studies (16;25). 
LITERATURE SYNTHESIS WITH DIRECTIONAL ASSESSMENT 
Evidence linkages are initially used for purposes of identifying relevant literature. This lit-
erature is reviewed and detailed information is extracted, including but not limited to patient 
data (e.g., clinical condition, age); data regarding the treatment, procedure, or anesthetic 
intervention: outcomes reported; and research design and statistical analyses. Spreadsheet 
technology applied to this task is invaluable, particularly in the subsequent management of 
the data and summarization of findings. The use of such technology can greatly reduce the 
time and effort spent aggregating the data. 
In their spreadsheet documentation, the ASA includes a classification value of the 
predominant "direction" of study findings. For each reviewed study, the outcome of interest 
is classified as supporting a linkage, refuting a linkage, or neutral. Each article is coded (i.e., 
support= +1, refutation = -1, neutral = 0), and a summary value is calculated across 
all studies. From these results, a directional (one-tailed) assessment of support or refutation 
for each linkage is obtained. Following the directional assessment, the evidence linkages 
are revised to include directionality, therefore providing justification for the use of one-
tailed statistical testing. A directional statement derived from the evidence linkage example 
cited earlier would be: "epidural bupivacaine with opioids improves maternal analgesia 
during labor compared to equal concentrations of epidural bupivacaine without opioids." 
All studies with data, regardless of methodology, are included in the directional assessment. 
No attempt is made to calculate average values or other aggregate statistics. 
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The directional overviev of the literature is viewed as a tool to refine the evidence 
linkage in order to initiate scJ.tistical procedures (i.e., meta-analyses). The directional as-
sessment represents a separac md vital component of the literature-based evidence because 
it is an examination of all s:r<iies, including those for which effect size estimates are not 
provided (i.e., case reports. :escriptive studies, correlational studies). These studies are im-
portant to evaluate because ::ey contain information not necessarily found elsewhere, and 
their inclusion can affect the .irectional assessment. For example, case reports may provide 
an indication of adverse out:.:cmes or previously unrecognized benefits not recorded in the 
clinical trial literature. Moc~~ver, descriptive studies provide evidence related to the fre-
quency of occurrence of an :c. erse or beneficial outcome when an intervention of interest is 
employed. 
ANALYTICAL PREPAR,!.-;"iON 
Once the directional overviev cs complete, the evidence linkages are refined to include one-
tailed hypotheses so that fo=al meta-analyses can proceed. At this point, only controlled 
comparative studies are cons:cered for analysis. Controlled studies provide a vital indication 
of the effectiveness of a me.:ical intervention. 
In the meta-analytic pc:cedures utilized by the ASA, the primary interest has been 
to combine original (prima:-_• research studies for purposes of investigating questions of 
causality. In this effort to :i:c:.1ment causal relationships, the design features of the vari-
ous studies under review a:-o Jf critical importance. If the studies comprising the primary 
research literature have des:p features that assure a high level of internal validity (e.g., 
random assignment of subje::s to conditions of the study, researcher and practitioner blind-
ing, and researcher control >er the intervention), then questions regarding causality can be 
addressed. When threats to ::rernal validity are evident in the primary studies under review 
(e.g., treatments administe·e~ :o pre-existing groups), then analyses cannot directly address 
questions of causality and '"" limited to questions of covariation. In summary, literature 
review can generally dete=e associations between variables of interest, but the investi-
gation of questions of cauS£.:irv is critically dependent on the inferential robustness of the 
controlled studies under re' ·-'e'-v. 
ANALYTICAL MODEL 
Meta-analysis 
When an evidence linkage :::ntains a sufficient number of studies (e.g., five or more) with 
well-defined experimental :esigns and statistical information, formal meta-analyses are 
conducted. A fixed-effects =cdel using odds ratios or combined probability tests is applied 
when there is an expectatio: :f minimal variation in effect size estimates among the studies 
in the analysis. 
A fixed-effects model s used more commonly for several reasons. Historically, the 
anesthesia literature has use: :he same or very similar outcome measures (e.g., visual analog 
scale scores for pain meastc:nent). Variability in outcomes among the various independent 
studies has generally been :cmogeneous. Conceptually, directional nonrandom outcomes 
are generally expected in ::e mesthesia literature. On occasion. a random-effects model 
may be considered when a:r:reciable effect size variability is expected. 
Usually, more than on; :est statistic is obtained in a meta-analysis related to a par-
ticular evidence linkage. F:r a meta-analysis to be supportive of an evidence linkage, all 
component analyses musT :c in agreement regarding effect sizes and significance values. 
As a further assurance of ::e congruity and robustness of the findings, all meta-analyses 
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should be in agreement with the directional lSsessment as well as with consensus opinion. 
When agreement is not apparent in any of the specified areas of evidence, further evaluation 
is necessary, and, if the disagreement conti::-c.es to persist, the discrepancy is reported and 
discussed in the guideline. 
Methodologic controls 
As a methodologic control for reviewer bias..1dditional assessments of the reviewed litera-
ture are conducted independently by the task ~orce members and methodologists. The ASA 
uses a sample of reviewed articles randomly o.=iected from each evidence linkage and a ran-
dom sample of articles not accepted into the ::arabase to assess agreement for study design, 
type of statistical analysis, identification of =-•idence linkage, and the reviewers' judgment 
as to whether the study should be included::: :he database. Interobserver agreement among 
task force members and methodologists is ac.:essed and reported using agreement levels for 
two-rater agreement pairs (17) and for mul:::-carer chance-corrected agreement ( 11; 12). 
Following review of the literature, tes:c :or heterogeneity of findings from the inde-
pendent studies are conducted to ensure COJO':stency among the study results. To control for 
potential publishing bias, the ASA calculac=.' 1 fail-safe N value for each combined prob-
ability test. A fail-safe :'-1 refers to the nurr:~er of additional studies necessary to increase 
the overall probability Yalue obtained to a "C:•1e higher than the critical value for statistical 
significance (16). To ensure that the literac.::::ce considered is peer-reviewed, no search for 
unpublished studies is conducted. The AS.'- ioes not conduct reliability tests for locating 
research results, because their intent is to c-~uin an entire population of published studies 
for each evidence linkage rather than collec=g a representative sample of studies. 
CONSENSUS AS EVIDENCE 
Research findings from published literature ~rovide the cornerstone for guideline recom-
mendations. However, published studies C.:.: ne may not provide necessary or complete 
information regarding relevant details of ct=cal practice. Accordingly, additional sources 
of information and eYidence are actively z=d deliberately sought by the ASA. Such in-
formation may best be obtained from clini~:.:.: experience. For example, studies examining 
preoperative testing may provide inform~:.·:n about the sensitivity and specificity of a 
particular test withour providing insight ~~':ur when or on whom a test should be per-
formed. Practitioner opinions may serve :' ' role as a supplemental source of evidence, 
reflecting current practice. Topics that are :.cdressed by obtaining practitioner opinion in-
clude issues related to the importance anc :ncticality of the interventions identified in 
a guideline, and issues related to the projo·::ed cost. estimated practice time, and feasi-
bility of implementing a guideline. Practi;j :cer opinion may be obtained through several 
mechanisms, ranging from tbe simple rec:rding of consensus within a designated task 
force to large-scale surveys and feedback :'::Jm presentations or open forums at national 
conventions. 
The ASA obtains consensus data fro:::: :::mltiple sources, including surveys of expert 
consultants and of the broader population :c practitioners. and open forum presentations, 
Internet commentary. and feasibility studio>'. Expert consultants are carefully chosen to 
provide a balance between private practic~ -'lld academia. as well as representation from 
each of the major geographic areas of the l'~~:ed States. Consultants are asked to participate 
in surveys of their opinions of various aspe::o of a guideline and to review and comment on 
initial draft reports. Random samples of th~ .\SA membership are also surveyed regarding 
the topics addressed by the evidence linb;cs. 
Each task force holds one or more oper: c:rums at a major national anesthesia meeting to 
solicit input on its draft guideline from mee::.:~ ottendees. During each open forum, audience 
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testimony is recorded. Directly following an open c;xum, the task force meets, commentary 
is discussed, and clarifications in the draft docume::c may be made. Major issues, when they 
arise, may require a new literature synthesis or a,c,';tional consensus surveys. The revised 
draft is then disseminated to varions additional '''urces (e.g., the Internet, ASA district 
directors, presidents of ASA component societiec ~or their commentary. The consultants 
are surveyed one final time to assess their opinio::s on the feasibility of implementing the 
revised guideline recommendations. All available :nfonnation is used by the task force to 
produce a final document for submission to the ·-'-"·"- for formal approval. 
The tenn consensus in this sense refers to c= c:valuation of the combined agreement 
derived from the sampling of opinions from scien:::.Ocs. experts, academicians, and clinicians. 
Surveys used to elicit and measure these opinion> 2re designed so that responses are easily 
interpreted and differences, when they occur, e.:-e ~!early noted. The opinions of survey 
respondents are based on sets of items that are :eliberately the same for each group of 
respondents. Responses from several sources can :':us be conveniently compared. 
Each consensus survey item is derived fro= 1 specific evidence linkage. Since the 
evidence-linkages are also employed in the literar.:: search and assessment procedures, the 
same set of intervention/outcome relationships pc:vides a constant foundation throughout 
the entire guideline development process. 
The use of consensus as a source of evidence ~~s not been thoroughly explored. How-
ever, consensus data often provide critical feeC:c~ck on the feasibility of the proposed 
recommendations. "Consensus as evidence" is ~ ceiatively distinct component of ASA's 
process. These data are analyzed in the same ~-mer as directional evidence, and thus 
become the third major evidence source for the ~:cmlation of viable recommendations. 
GUIDELINE RECOMMENDATIONS 
Guideline recommendations are based directly on c:::e evidence linkages developed at the be-
ginning of the process. Each of the three sources C·c o'iidence (i.e., directional, meta-analytic, 
and consensus) is separately considered in the fo=ulation of the final recommendations. 
Agreement among the three sources of evido:::ce is required for the full support of a 
recommendation related to a particular evidence iukage. Occasionally, divergence from 
the full support of all three sources may occur. F:r example, meta-analytic and directional 
results may support a designated intervention. be ~-:eir application in clinical practice may 
be questioned by consensus findings. These d:· .. ~cgences are noted, then discussed and 
interpreted in the guideline. By discussing the s::cc::cgths and shortcomings of each recom-
mendation, a guideline becomes sufficiently dyncc to respond to the diverse requirements 
of clinical practice. 
CONCLUSIONS 
The process described herein represents the colle:·::se efforts by the ASAto produce timely 
and clinically relevant guidelines. In particular. =e use of an exhaustive literature search, 
literature synthesis, directional summarization. =toea-analyses, and consensus assessment 
all combine to produce a multifaceted overvie" :r evidence for rational policy decision 
making in clinical medicine. These activities ace: ::::cade easier and more accurate through 
the use of existing technology. such as refereu::e databases (for literature searches and 
citation management), spreadsheets (for literature 1ggregation and analysis), and statistical 
software (for survey assessment). 
The AS A's evidence-based model for guide'~e dexelopment combines literature syn-
thesis and analysis with the knowledge and ex::ecience obtained from clinical practice. 
The accumulated scientific data coupled with the :·ecognition that practitioners on occasion 
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may need to modify procedures to fit individual cases fonm 1 compelling basis for the 
widespread acceptance and use of practice guidelines. 
When there is not sufficient information available for the :tOvelopment of an evidence-
based practice guideline. an alternative may be considered. On= alternative that has recently 
been implemented by the ASA is the practice advisory (1·····. The intent of a practice 
advisory is to systematically use an evidence-based model w:::out meta-analytic findings. 
Therefore, until meta-analytic evidence becomes available, a ;n.ctice advisory, in the form 
of a published report, may be used as a viable reference doc=em for clinical practice. 
Through the dissemination of practice advisories in conju:ccion with practice standards 
and guidelines, the ASA makes available a complete pacb.?= of advice to clinicians on 
selected topics. Practice standards offer guidance for nanov md well-defined areas of 
practice, while guidelines and advisories are intended to addr~::; che more complex aspects 
of patient care and may provide information on the impact :i e1ew medical technologies 
or other recent interventions. These three sources of guidanc~ ,-hen periodically updated, 
will offer practitioners access to the most recent collective l::cwledge relating to patient 
care. 
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